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Superficially it might be said that the function of the kidneys
is to make urine, but in a more considered view one can say
that the kidneys make the stuff ofphilosophy itself.
Let our kidneys fail for even a short time to fulfil their task,
and our mental integrity, our personality, is destroyed.
Homer W Smith, 1940
Lectures on the Kidney
Abstract
The principle aim of this thesis is to examine the hypothesis that patients with acute renal
failure (ARF) who are treated with high dose loop diuretics have a better prognosis in terms
of survival, need for dialysis and speed of recovery than those who do not receive these
drugs.
A prospective, double blind, randomised, placebo controlled study was carried out on 94
patients with ARF in Glasgow Royal Infirmary. The use of loop diuretics caused a
significant increase in urine output and fractional excretion of sodium in the first 24 hours,
but had no effect on the final outcome (recovery, dialysis or death) at day 21. Patients who
became non-oliguric (with or without loop diuretics) had a better survival but were less ill
(APACHE II score 17.2 v 20.6, p=0.007, non-oliguric v oliguric) and had less severe renal
failure (creatinine clearance 14ml/min v 4.5ml/min, p<0.0001) than those who remained
oliguric.
Loop diuretics can lower cytosolic calcium in normal individuals and in those with
hypertension. Because cell death has been shown to be accompanied by a rise in
intracellular calcium, I postulated that cytosolic calcium levels would be high in patients
with ARF. Further, the use of loop diuretics might lower cytosolic calcium in patients with
ARF and thereby exert a beneficial effect on renal tubule cells.
Intraplatelet calcium levels were high in patients with ARF compared to normal controls
(109nm v 92.4nm, p=0.004). Administration of a loop diuretic had no effect on intraplatelet
levels of calcium.
1 hypothesised that this rise in intracellular calcium might be related to the severity of illness
and thus correlate with the APACHE II score, an objective scoring system used to stratify
patients according to prognosis. No correlation was found.
I
Finally, indirect calorimetry is an accurate, although painstaking, method of measuring
energy expenditure in the critically ill patient. Metabolic rate may be related to clinical
outcome. If the resting energy expenditure (REE) correlated with the APACHE II score, the
latter, simpler measurement could be used as part of a formula to predict metabolic rate.
My studies of REE in patients with ARF showed no correlation with the APACHE II score
which should therefore not be used to predict energy expenditure in ARE. Nor was there
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1 Historical Perspective - before 1965
1:1 Pathophysiology of acute renal failure
1:1:1 Pathology
In 1912 Suzuki described the pathological appearance associated with a number of
nephrotoxinsJ The lesions were specifically located in the proximal tubules, but later these
findings could not be confirmed by other pathologists. Renal impairment due to crushing
injury had been noted by Frankenthal during the 1914 - 1918 war,2 although the importance
of the lesion was not emphasised until 1923.3
During the Second World War pathologists became particularly interested in patients with
crushing injuries to skeletal muscles, but no direct damage to the kidneys. These victims
died from uraemia and histological examination of the kidneys showed complete tubular
disruption, especially in the distal tubules, with intratubular obstruction by casts.
In 1941 Professor Shaw-Dunn described the renal lesions in victims of the Glasgow air raids
who died from crush syndrome, noting the severe lesions in the distal nephron.4 Bywaters
and Beal also published extensively and brought acute renal failure (ARF) into the
limelight. They described the pathological appearance of the kidneys in patients dying from
crushing injuries to skeletal muscle during World War II.5-9 Only the distal tubules and the
collecting ducts were believed to be affected.
Lucke coined the term 'lower nephron nephrosis' and stated that it was present in 10-20% of
deaths resulting from battle wounds in World War 11.10 pje showed that a variety of
disorders, shock, trauma, transfusion reactions etc resulted in the same pathological
appearance rather than specific appearances as previously believed. Changes were shown to
be '...selectively restricted to the lower segments of the nephrons...'. He felt that several
factors were involved in the pathogenesis, including degradation products ofmyoglobin and
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haemoglobin, products of tissue breakdown, alteration of renal blood flow and changes in
the chemical milieu of blood. He also showed that the renal lesion was recoverable and that
if the patient survived complete regeneration of the renal tubules occurred.
The morphological picture which finally emerged from these early studies was as follows.
Macroscopically two main types of kidney were seen. In those who died early the capsule
stripped off easily and the cortex had a yellow glistening texture. In those who died later
the kidneys were cyanosed, although the cortex was again yellow. The capsule was
unwrinkled. The glomeruli were usually normal in appearance although sometimes the
vascularity appeared reduced and the capsular space contained granular eosinophilic
material. Early degenerative changes were noted in the proximal tubules with a 'catarrh'
made up of cell debris or precipitated protein.9,10 The changes in the proximal tubule were
minimal compared to the distal tubule, although amorphous debris was seen in the latter.
There was no pigmentation of the contents of the proximal tubules. The descending limb of
the loop of Henle looked normal, although some 'mild catarrhal changes' were sometimes
present. The major abnormalities were in the thick ascending limb of the loop of Henle and
the distal tubules. Focal areas of degeneration, necrosis and regeneration were scattered
throughout this part of the nephron. Areas of necrosis were surrounded by an inflammatory
infiltrate of lymphocytes and histiocytes. Later fibroblasts appeared and destroyed
parenchyma was noted to be replaced by scar tissue. It was noted that degeneration rarely
occurred before day 4, but after that necrotic tubule cells disintegrated and disappeared. By
day 10 regeneration of necrotic areas had occurred. Sometimes a tubule ruptured with
protrusion of a cast into the interstitial tissue. Occasionally tubules ruptured into veins
Hyaline casts were common in the thick ascending limb and pigment casts became more
numerous in the distal tubule. According to Bywaters and Dibble they were particularly
numerous in the collecting ducts, although Lucke reported that the collecting ducts were
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almost normal.9,10 Darmady suggested that the composition of casts depended on the
length of survival. 11 Early casts consisted largely of hyaline material, whereas in those
dying later pigment casts were predominant. Sometimes pigment casts formed round a
central focus such as a fragment of degenerate epithelium or a sulphanilamide crystal.
The disputes over the pathological lesions occurring in anuria were resolved by the
meticulous microdissections of Dr Jean Oliver and co-workers in 1951.12 Dr Oliver was
sent specimens of kidneys by Professor Shaw-Dunn from Glasgow and he also received post
mortem material from the United States from patients dying from a variety of nephrotoxins
such as mercuric chloride, potassium diclonate and also from patients dying from ARF post
operatively. Oliver carefully microdissected hundreds of whole nephrons. Two distinct
types of nephron damage were found. The first type showed focal lesions with destruction
of the entire tubule wall, including the basement membrane, throughout the entire length of
the nephron. He called this tubulorhexis. An example from a victim of the Clydebank Blitz
is shown in Figure 1:1. This demonstrates only the distal nephron. Similar changes were
found throughout the proximal tubule. The second histological picture was much more
localised and related to nephrotoxic damage by specific nephrotoxins (Figure 1:2).
1:1:2 Function
Early micropuncture studies gave rise to three theories as to the aetiology ofARF.
1. Backdiffusion of filtrate through damaged tubule walls causing oliguria was first
suggested in 1929.13 Using kidney micropuncture techniques, Richards noted that in frogs
poisoned with mercuric chloride, tubules, which were normally impermeable to dye,
allowed leakage of the dye into the interstitium.
2. Tubule obstruction by the casts seen histologically in the dilated tubules. The original
theory that ARF was caused by epithelial debris and casts causing intratubular obstruction
was put forward by Barratt and Yorke (1909) and supported by Baker and Dodds (1925) and
1-3
Morrison (1941). 14-16 Micropuncture studies looking at increasing intratubule hydrostatic
pressure were conflicting, depending on the model studied and the stage of evolution of
ARF.14-16 Taken over all, the studies showed that intraluminal hydrostatic pressure was
not consistently raised during the early or late stages of experimental ARF. Many believed
that in the presence of reduced single nephron glomerular filtration, sludging would occur
causing tubule casts to be formed and thus perpetuation of ARF, ie tubule obstruction had a
secondary rather than a primary role in the development of experimental ARF.
3. In 1945 Bywaters proposed that tubule ischaemia was critical and that the presence of
casts was incidental.! 1 Corcoron and Page (1947) divided post traumatic anuria into two
groups - those with tubule obstruction by casts and those with tubule necrosis.!7,18 They
noted that beefmetamyoglobin injected into healthy dogs caused little renal damage but that
the addition of renal ischaemia caused the animal to die from renal failure within 24
hours. 17 They also suggested renal ischaemia causing oliguria and associated with
acidaemia predisposed to the formation of protein casts in the tubules. Thus renal ischaemia
was important for the development of both histological pictures.
Bywaters and Dibble believed that true lower nephron nephrosis was associated with casts
in the distal tubule while pointing out that mechanical blockage could not be the sole
responsible agent.8,9 They drew attention to patients who died from anuria complicating
crushing injuries but who had very little in the way of casts. They suggested that if tubule
obstruction were the only factor involved in anuria, then any urine passed would be of
normal composition having been excreted by unblocked, apparently normal nephrons. Of
course the urine was not normal and appeared to be poorly concentrated glomerular filtrate,
suggesting a disruption in tubule function.
Tomb (1942) first suggested that decreased renal blood flow would cause damage in those
areas of the nephron supplied last by the blood ie the loop of Henle, where maximum
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damage was found. 19 in 1942 Trueta showed that localised trauma leads to widespread
arterial spasm and suggested that this might result in renal anoxia.20 Cournand (1943) and
Lausen (1944) proved that vasoconstriction of renal arteries occurred in shock,21,22 while
others showed that temporary experimental occlusion of renal arteries caused a picture
similar to traumatic uraemia.23 Maegraith (1944) argued that the anuric state was due to a
temporary decrease in glomerular filtration resulting from altered vascular flow, rather than
primary obstruction of the tubules.24,25
1:2 Modification of acute renal failure
No measure is known that will restore a physiologically ruined kidney
except time and the organ's intrinsic reconstitutive power'
Homer W Smith (1951)26
The earliest attempts to treat patients with acute renal failure did more harm than good.
Clinicians assumed that expanding the intravascular volume might initiate a diuresis, but the
over administration of fluid merely hastened the demise of the patient by causing fluid
overload and pulmonary oedema.27
Renal decapsulation, first performed by Edebohl in 1898,28 was favoured in the early
1940's as a method of relieving the renal oedema seen by some microscopically.28 Peters
proposed that renal oedema caused an increase in intrarenal pressure, effectively preventing
the flow of urine.29 However, by the early 1950's this procedure had been abandoned for
several reasons. First of all it was recognised that the renal oedema was probably due to
over administration of saline. Secondly, decapsulation was a last resort by which time the
patient was usually moribund. Finally the operation itself was potentially harmful in these
sick patients. Peters noted that those successes reported in the literature indicated that renal
decapsulation was performed between the 8th and 1 Cf'1 day, the time when a spontaneous
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diuresis most often occured.29 Styron and Leadbetter (1945) carried out unilateral
decapsulation in a case ofARF and by ureteric catheterisation demonstrated no difference in
function in either kidney.30 Culpepper and Findlay (1947) pointed out that the tubule
lesions were most important in maintaining oliguria and said that there was little evidence
supporting increased intrarenal pressure as a significant aetiological factor.3 !
In 1944, in a personal communication to Darmady, Trueta suggested that a splanchnic block
might prevent renal vasoconstriction.! 1 Darmady then successfully tried renal denervation,
using procaine infiltration of the splanchnic nerve, on two patients.! 1 McGowan and Antry
reported the successful treatment of a 19 year old male with a procaine sympathetic
block.32 Others had less favourable results.33
Those patients who were not 'drowned' by over zealous administration of fluid died from
arhythmias secondary to hyperkalemia. In 1950 Hicks et al showed that an innovative
method of obtaining extra-renal clearance of urea and creatinine was by small intestinal
lavage.34 Peritoneal lavage was also shown to be effective at removing nitrogen from the
body.35.36
The early treatment of anuria was therefore mainly conservative. Circulatory failure was
corrected, salt and water administered as necessary and infection treated. Dietary sodium
was restricted in all patients who were not dehydrated, as sodium retention would lead to
water retention when water might otherwise have been excreted. Patients were given
glucose-fat emulsions to provide calories in a non-protein diet and thus reduce endogenous
protein catabolism to 1/3 of its starvation level. It was possible for a patient managed in this
way to continue for at least a month before the urea concentration rose above 300mg%.37
In 1943 Kolff first used his artificial kidney to treat a patient with ARF. In his book 'The
Artificial Kidney' he describes the first 14 patients with ARF treated by this method. 38
The initial experience was not good and 12 out of the first 13 patients died. Kolff admits
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that the patient who survived would probably have done so without dialysis. The high
mortality was attributed to the serious clinical condition of the patients and the late referral
for dialysis. Despite the depressing statistics, Kolff remained confident that he and his
colleagues would one day be able to say 'He is cured, and without the artificial kidney he
would have died',38
The 14th patient probably had acute tubular necrosis secondary to acute cholecystitis and
proved Kolff to be correct - without dialysis she would have died.
1:3 Summary
Although peritoneal dialysis and the artificial kidney were in use by the early 1950's, Homer
Smith comments that 'they cannot in themselves induce a diuresis and their value in
influencing the course of acute anuria, usually a self limited disturbance, defies critical
evaluation'.26 Until renal replacement therapy became standard practice for patients with
ARF therapeutic measures were aimed at keeping fluid and electrolyte balance normal,
reducing endogenous protein catabolism to minimum and preventing infection and
circulatory failure.
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Figure 1:1 Crush anuria - young woman pinned under a beam for six hours 12
A. Rupture of basement membrane and tubular wall
B. Tubule distended with a black pigment cast
C. Fragmentation of the tubule wall
D. Regenerating tubule epithelial cells
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Figure 1:2 Localisation of nephrotoxic damage in various forms of poisoning 12
1. Potassium bichromate; 2. Uranyl nitrate; 3. Corrosive sublimate; 4. Sodium potassium
tartrate; 5. Potassium chlorate; 6. Di-ethylene glycol; 7. Carbon tetrachloride; 8. Mushroom
poisoning; 9. Serine; 10. Sulfonamides.
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2 Current Knowledge - after 1965
2:1 Pathophysiology of acute renal failure
Hypoxic injury to renal tissue results in cell damage due to inadequate energy and substrate
provision to meet the tissue's metabolic demand. The pathogenesis of ischaemic acute
renal failure due to hypoperfusion of the kidney is complex and there are many interrelated
mechanisms which together initiate and promote ischaemic renal damage.
2:1:1 Pathology
After sixty minutes of ischaemia changes are seen in proximal tubule brush borders.39
Microvilli disintegrate and are shed into the tubule lumen. Tubule cell cytoplasm is
extruded into the lumen and forms dense, free floating spherical bodies. There is no plasma
membrane and it is unclear how the limiting membrane is formed. These "blebs" of
cytoplasm are much more densely packed in the proximal straight tubule than in the
proximal convoluted tubule (PCT). Twenty-four hours later these "blebs" have disappeared
and have presumably been degraded into amorphous debris. The distal tubules, collecting
ducts and thin limbs of the loop of Henle contain casts formed from cellular debris and
Tamm Horsfall protein. All the proximal straight tubules and about half of the proximal
convoluted tubules have epithelial necrosis. The damage occurring after sixty minutes of
ischaemia is much less severe in the proximal convoluted tubules than in the proximal
straight tubules.
After 25 minutes of ischaemia, Donohoe showed that damage to the proximal convoluted
tubules was much less severe, with interiorisation of microvilli into epithelial cell
cytoplasm.39 These changes are reversible and microvilli are regenerated 30 - 60 minutes
after reflow. Irreversible changes with signs of necrosis were present in some of the
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proximal straight tubule cells. These cells were shed into the lumen and the epithelium
subsequently regenerated. Venkatachalam et al also showed that within 5 minutes of
reperfusion after 25 minutes of renal artery occlusion, most of the brush border microvilli in
all three segments of the proximal tubule were interiorised into the cytoplasm of the
proximal tubule cells.40 The Sj and S2 cells showed complete regeneration of microvilli
by four hours and cells appeared morphologically normal. Cells in the S3 segment however
showed signs of irreversible cell injury and were exfoliated into the cell lumen.
Fifteen minutes of ischaemia resulted in mild morphological changes that had completely
reverted to normal after 30 minutes of reflow. Thus the severity of morphological damage
appears to be related to the duration of ischaemia.
2:1:2 Intratubular obstruction
After sixty minutes of ischaemia a rise in proximal intratubular pressure can be
demonstrated which rises further following microinjections of small volumes of fluid.41,42
Further injections of larger volumes of fluid did not cause a rise in intratubular pressure
implying that the initial injection had flushed out the obstruction.43 Twenty-four hours
after reversal of ischaemia proximal tubule pressure was still elevated but only
approximately 50% higher than baseline pre-ischaemic pressures.44,45 Arendshorst et al
noted greatly increased proximal and distal tubule pressures of 31 and 16mmHg
respectively (controls 11.5 and 5.3mmFIg).41 Twenty four hours later proximal tubule
pressure had decreased to 9.2mmHg. However, acute volume expansion at this time caused
a rise in intratubular pressure implying that the tubules were still blocked.41
Morphologically casts are still present a week after the ischaemic event but by two weeks
the tubules are patent and fluid injections do not produce a rise in intratubular pressure.44
Donohoe used intrarenal inulin sequestration as a measure of tubule obstruction.45 After 15
minutes of ischaemia, and in control animals, recovery of inulin was complete. After 25
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minutes of ischaemia 12% of inulin injected into the ischaemic proximal convoluted tubule
was not recovered in the urine. This increased to 28% after 60 minutes of ischaemia. About
73% of the missing inulin was found to be sequestered in the ischaemic kidney.
2:1:3 Backleak of filtrate
Using microinjection techniques the tubule epithelium can be shown to be abnormally
permeable due to cell necrosis, and the degree of permeability is related to the duration of
ischaemia.45,46 After microinjection of inulin into the PCT of control animals, recovery of
inulin from ipsilateral urine was virtually complete. This was also the case after 15 minutes
of renal artery occlusion. However, after 25 minutes of ischaemia 10.8% of injected inulin
was recovered in the contralateral urine, increasing to 34.9% after sixty minutes of
ischaemia.45 Tanner and colleagues kept the intratubular pressure constant during
microinjection of inulin, and showed that backleak is not an artefact due to transient rises in
intratubular pressure forcing fluid across the damaged epithelium, but is due to a genuine
increase in tubular permeability.46
This is in keeping with Richards' original theory of 1929.26
2:1:4 Vascular congestion
Following temporary experimental ischaemia there is vascular congestion in the inner stripe
of the outer medulla,47 and the accumulation of erythrocytes is such that normal blood flow
is not possible.48,49 N0 fibrin deposition or platelet aggregation can be seen
histologically,48 and as prior heparinisation and administration of aspirin had no effect on
post ischaemic renal function, the participation of haemostatic mechanisms seems
unlikely.49,50
The cause of the vascular congestion is not clear but there are several possible contributing
factors. The anatomy of the medullary vasculature is thought to predispose to erythrocyte
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aggregation: the parallel capillary circuits may slow blood velocity to such an extent that
during ischaemic events a further reduction in flow rate promotes stagnation of
erythrocytes. It can be postulated that hypoxia and substrate deficiency lead to depletion of
intracellular adenosine triphosphate (ATP) and therefore inactivity of the ATP dependent
Na/K pump. The resulting impairment in cell volume regulation allows cell swelling due to
movement of extracellular fluid into the intracellular space. Karlberg showed that labelled
albumin accumulated in the medullary interstitium during recirculation after ischaemia.51
This leak of plasma would cause a rise in haematocrit. The combination of reduced plasma
volume, increased haematocrit, cell swelling, and reduced blood flow rate promotes
aggregation of erythrocytes, which restricts reperfusion after the ischaemic event leading to
irreversible cell damage and tubular necrosis.
The degree of functional loss has been shown to be related to the severity of vascular
congestion, with the most severe degree of hyperaemia associated with the lowest filtration
rate, poorest concentrating ability, most depressed reabsorptive capacity, smallest urine
volume and lowest blood flow rate.48 The disappearance of medullary hyperaemia
occurred concurrently with restoration of deep glomerular blood flow, and the return of
concentrating ability in the recovering kidney.
Tubule cells in the outer medulla normally operate on the brink of hypoxia and are therefore
extremely sensitive to episodes of hypoxia.52 This is particularly so for those tubules
situated at a distance from nutrient blood vessels.53,54 There are three possible
mechanisms for preventing tubule cell death by limiting vascular congestion:
1. Increasing perfusion pressure
2. Lowering haematocrit
3. Reducing cell volume
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Mason et al have shown that increasing renal perfusion pressure and reducing the number of
circulating erythrocytes without any volume expansion, both cause a reduction in the degree
of medullary congestion and an improvement in renal function.55 They showed the
fdtration rate and tubular reabsorption could be raised from 20% to 60% of normal 3 and 18
hours after ischaemia in rats.
Reducing cell volume can be achieved by administration of hypertonic mannitol. Giving
hypertonic mannitol before ischaemia has been shown to confer protection on renal
function.56,57 This is presumably due to the rise in plasma osmolality limiting the
movement of extracellular fluid into the intracellular space and so limiting cell swelling and
vascular congestion. Mannitol also causes expansion of the plasma volume which will
reduce haematocrit.
All three of these manoeuvres had exactly the same effect on renal function, each causing an
increase in fdtration rate and tubular reabsorption to 60% of control,58 and this despite
completely different modes of action; lowering haematocrit prevents erythrocyte
aggregation, increasing perfusion pressure reverses stasis and congestion while mannitol
prevents cell swelling. However, the end result common to all three methods was an
increase in perfusion to the deep nephrons, delivering oxygen and substrates necessary for
recovery.
2:1:5 Renal blood flow
Renal blood flow (RBF) is decreased by up to 50% during the first six hours of reflow
following ischaemia.59 Daugherty et al showed that incomplete renal ischaemia for three
hours caused a rise in afferent and efferent arteriolar resistance immediately after relief of
partial renal ischaemia.60 The cause of the increased vascular resistance is not clear, but
several hypotheses have been proposed.
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1. Endothelial cell swelling leading to a decrease in arteriole diameter and thus increased
resistance to blood flow was an early hypothesis.61 It has since been rejected on the
grounds that cell swelling is mainly tubular and not vascular.40
2. Ischaemia is known to cause a rise in plasma and intrarenal renin activities which may
lead to angiotensin II production, so causing vasoconstriction.62 in human studies, plasma
renin levels have been shown to be elevated during the phase of established ARF.63,64
During the diuretic phase of ARF plasma renin levels fell to normal. Unfortunately,
presumably due to the difficulty in predicting when ARF is going to develop, renin levels
prior to the development of ARF have not been looked at to determine whether an increase
in plasma renin is necessary for the development of ischaemic ARF. However, angiotensin
converting enzyme (ACE) inhibitors do not appear to modify the course of ARF despite
increasing renal blood flow,65 and chronic suppression of renal renin by salt loading does
not prevent the decrease in glomerular filtration rate (GFR) seen after 45 minutes of
ischaemia.66
3. Increased solute delivery to distal segments causes tubuloglomerular feedback and an
increase in vascular resistance.67
4. Numerous groups have shown impaired autoregulation of renal blood flow during the
maintenance phase of ischaemic ARF.68-71 Conger et al have shown that in a noradrenalin
induced model of ARF (NA-ARF), at one week a reduction in renal perfusion pressure
causes a paradoxical increase in renal vascular resistance.72 Renal nerve stimulation also
causes vasoconstriction and prostaglandin I2 (PGI2) infusion caused normal vasodilatation.
In a renal artery clamp model of ARF (RAC-ARF), there was no change in vascular
resistance in response to a reduction in renal perfusion pressure and renal nerve stimulation
did not affect renal blood flow.70 PGI2 infusion caused marked vasodilatation.
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In the first model <10% of resistance vessels showed smooth muscle necrosis, whereas 50%
of resistance vessels showed smooth muscle necrosis in RAC-ARF. NA-ARF caused
predominantly functional endothelial vascular injury and RAC-ARF caused predominantly
smooth muscle injury. This may be because renal blood flow in the noradrenalin model was
quantitatively less, although more sustained. The rate of recovery of blood flow may
determine the extent of vascular injury, and the slow recovery in NA-ARF may have
attenuated the severity of reperfusion oxidant injury.
Angiotensin and thromboxane both increase the vasoconstrictor response to renal nerve
stimulation,^2,73 an(j b0th hormones are elevated after ischaemic injury.71,74 Robinette et
al have shown that administration of an angiotensin II antagonist or a thromboxane A2
antagonist partially corrected the vasoconstrictor response to renal nerve stimulation and
renal perfusion pressure reduction.71 A combination of the two eliminated the
vasoconstriction due to renal nerve stimulation and also to a reduction in renal perfusion
pressure, but in the latter case appropriate vasodilatation was not restored. From this they
conclude that there are two components of abnormal renal blood flow autoregulation in NE-
ARF.
a. Paradoxical vasoconstriction to renal nerve stimulation or a reduction in renal perfusion
pressure, mediated by angiotensin II and thromboxane induced adrenergic hypersensitivity.
b. Inability to vasodilate in response to myogenic or tubuloglomerular feedback stimuli.
In a clinical setting it may be that the maintenance phase of ischaemic ARF is accompanied
by additional insults such as repeated ischaemic episodes. Loss of renal blood flow
autoregulation would mean the kidney would be unable to protect itself from falls in renal
perfusion pressure causing further ischaemic damage. Fresh tubular necrosis would occur
and prolong the duration ofARF.
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5. Endothelium derived relaxing factor is depressed after ischaemia and it may therefore be
involved in the vasodilatation produced after a reduction in renal perfusion pressure.75 in
its absence, appropriate vasodilatation may not occur.
6. Calcium may leak back into the ischaemic smooth muscle cells and so cause
vasoconstriction.76
2:1:6 The role of prostaglandins
Prostaglandins are involved in autoregulation of RBF and glomerular GFR, renin release,
tubule ion transport and water metabolism. However, their role in ARF is unclear. There
are several potential prostaglandin sensitive pathophysiological mechanisms in ARF.
a. Autoregulation of renal blood flow. Prostaglandins of the Ej, Dj and I2 series dilate the
intrarenal vessels.77 However, there is controversy over whether or not local prostaglandin
release is necessary for autoregulation of RBF and GFR.78-80
b. Tubuloglomerular feedback, which may be involved in the pathophysiology of ARF,
requires an intact prostaglandin system to operate.81>82
c. A reduction in the glomerular capillary ultraftltration coefficient (Kf) may contribute to
the decline in GFR. Prostaglandin Ej has been shown to diminish Kf83 as has bradykinin -
a vasodilator that mediates its effect partly by prostaglandins.84
d. Capillary reflow. Endothelial PGI2 release may prevent vascular aggregation and
maintain vascular patency.85 Indomethacin has been shown to increase the injury in the
medullary thick ascending limb of the Eoop of Henle in ARF,86 while an infusion of PGI2
and PGE2 has a protective effect on the proximal tubule structure.87 Also, the vasodilator
effect of mannitol in ARF has been shown to be due to PGI2 release.88 Thus, impaired
prostaglandin synthesis due to endothelial cell injury may contribute to the decrease in RBF
in the maintenance phase of ARF.
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e. The renin - angiotensin system. Angiotensin II may be involved in tubuloglomerular
feedback and also in controlling Kf.81,89 Prostaglandins modulate renin release and
activation of the renin - angiotensin system stimulates local prostaglandin release,90
therefore it can be seen that the interaction between the two systems may be an important
pathophysiological mechanism in ART.
2:1:7 The role of calcium
The extracellular calcium concentration is 10^ greater than the intracellular calcium
concentration (10~3 v 10"^). This difference in concentration is maintained by the relative
impermeability of the cell membrane to calcium. There are two main calcium extrusion
mechanisms;91
1. ATP dependent Ca-ATPase
2. Na/Ca exchange mechanism
Under normal circumstances buffering of cytosolic calcium is regulated by the Ca-ATPase
of the plasma membrane and the endoplasmic reticulum. Larger loads of calcium are dealt
with by the Na/Ca exchange mechanism and by mitochondrial uptake.92
The transport of electrons, derived from Krebs cycle, along the mitochondrial respiratory
enzyme chain situated in the inner mitochondrial membrane releases energy. This energy is
used to transfer hydrogen ions from the inner surface of the inner membrane to the outer
surface of the inner membrane so creating an electrochemical gradient. This
electrochemical gradient is the driving force for the formation of ATP from adenosine
diphosphate (ADP) and phosphorus (Pi). However, it is also the source of energy for
mitochondrial calcium uptake which occurs without being coupled to the movement of
another ion.93 The use of the electrochemical gradient for calcium uptake is at the expense
of ATP production. A highly significant correlation between increasing mitochondrial
calcium concentration and decreasing mitochondrial respiration has been shown,94,95
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presumably because mitochondrial calcium accumulation competed with oxidative
phosphorylation and ATP synthesis.96
During ischaemia, alterations in the cell plasma membrane phospholipid composition allow
an influx of calcium into the cell during the period of reflow, when more calcium is
delivered to the ischaemic area.95 Also during ischaemia there is reduced ATP synthesis,97
which may result in reduced ATP dependent calcium efflux. The rise in free intracellular
calcium ([Ca]j) during reflow is therefore buffered by the mitochondria and the result is an
uncoupling of oxidative phosphorylation. Arnold showed that mitochondria isolated after
ischaemia but prior to reflow were unable to buffer increases in [Ca]j.97 Buffering capacity
returned to normal after 3-6 hours of reperfusion but then deteriorated. After 18 - 24 hours
of reperfusion mitochondria were completely unable to regulate calcium.
The buffering of calcium by mitochondria causes a rise in mitochondrial calcium
concentration which uncouples oxidative phosphorylation. ATP production is reduced and
calcium efflux is impaired and there is a net influx of calcium into the cell. Mitochondrial
buffering of the cytosol becomes less effective, and as the [Ca]j rises there is equilibrium
between the mitochondria and the cytosol. This appears to be passive transfer of calcium
from the cytosol across a mitochondria membrane damaged by ischaemia, as neither an
increase in active uptake nor diminished release of calcium by mitochondria can be
demonstrated.97
The accumulation of intracellular calcium has other detrimental effects: elevated [Ca]j
activates energy consuming reactions such as sarcolemmal Ca ATPase and so further
depletes the cell ofATP.91 Phospholipases are activated causing an alteration in membrane
permeability and membrane enzyme activity.98-101 Degradation of membrane
phospholipids leads to the production of lysophospholipids and free fatty acids that may
cause further damage. Activation of intracellular proteases in the presence of a raised [Ca]j
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will convert xanthine dehydrogenase to xanthine oxidase which in turn leads to the
production of hydroxyl radicals.'02,103
2:1:8 The role of free radicals
Generation
Ischaemia leads to a depletion of intracellular high energy phosphates, and the hydrolysis of
ATP generates hypoxanthine.97 During conditions of ischaemia, the rise in intracellular
calcium causes xanthine dehydrogenase to undergo a proteolytic configurational change to
xanthine oxidase.'07,108 During reperfusion, and in the presence of molecular oxygen,
hypoxanthine acts as an oxidisable purine substrate for xanthine oxidase and is converted to
xanthine. In the process superoxide radical is generated (equation 1).' 04
Hypoxanthine + H2O + 202 xanthine oxidase > Xanthine + 2C>2"- +2H+ (1)
Superoxide dismutases (SOD) are naturally occurring free radical scavengers which rapidly
catalyse the conversion of 02"- to hydrogen peroxide (equation 2), which is itself toxic at
high concentrations and also inhibits SOD. The major problem with H2O2 accumulation is
that it reacts with 02"- to form molecular O2, hydroxide and hydroxyl radical (equation 3).
02~- + 02-- + 2H+ —SOD_> H2o2 + 02 (2)
H202 + 02"- —02 + OH" + OH- (3)
OH- is the most reactive and toxic of all the free radical species. Under normal
physiological conditions large concentrations of OH- do not exist as 02"- is scavenged by
SOD, and H2O2 by the catalase (equation 4) or glutathione peroxidase systems (equation 5).
2H202 —Catalase > q2 + 2H20 (4)
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2GSH + H202 GSSG Peroxidase > GSSG + 2h2o (5)
There are no scavenger systems that scavenge excessive concentrations ofOH-.
Oxygen free radicals (OFR) are also generated by auto-oxidation of catecholamines,
although the contribution of this to ischaemic renal damage is thought to be
insignificant. Endothelial cells may contribute to free radical production, either by
producing them or acting as a source of chemoattractants for polymorphs (PMNs).106
However, leukocyte production of free radicals does not play a major role in cell damage
until at least two hours after reperfusion, 107 and thus the main source of free radicals during
reperfusion after ischaemia is the xanthine oxidase reaction. 104
Effect of free radicals
In theory, free radicals could damage arterial endothelium, mesangial cells, and tubule
epithelial cells. Using a rat model, Galat and colleagues generated free radicals in the
absence of ischaemia, and showed a decrease in glomerular filtration out of proportion to
the reduction in renal blood flow. 108 Tubule function, however, was not affected in the
absence of ischaemia, although this may have been due to reduced delivery of filtrate to the
tubules. Had normal or even higher than normal loads of filtrate been delivered to the
tubule epithelium, tubule transport might have been impaired. However, the tubules did not
have any histological lesions of ischaemia. They propose that during reperfusion following
ischaemia the site of OFR generation is the tubules, rather than vascular endothelium. Also
neutrophils may be necessary for full expression of post ischaemic reperfusion injury as
neutrophil depletion has proved to be as protective as OFR scavengers in some
organs. 109,110
Endothelial cells appear to be more susceptible to oxidant injury than tubule epithelial cells,
and tubule epithelial cell lines with proximal tubule characteristics are more sensitive to
injury by OFR than distal tubule epithelial cell lines. 11 1
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It has also been shown that mitochondria in the rat renal cortex exposed to injury by free
radicals alone develop only a mild impairment of respiratory function, implying that other
factors must be contributing to ischaemic renal damage. 112
Paller et al demonstrated that inhibition of free radical generation using the xanthine oxidase
inhibitor allopurinol, provided protection against renal impairment after ischaemia.l 12
Likewise, scavenging of C>2~- with SOD or OH- with dimethylthiourea afforded protection
after ischaemia. However, the protection afforded by the scavengers was incomplete, again
implying that other factors contribute to ischaemic renal damage.
Others have shown that prevention of free radical formation by a xanthine oxidase inhibitor
prevented erythrocyte accumulation in the medulla, which may have contributed to the
lower peripheral resistance and higher blood flow observed immediately after reflow.l 14 It
is postulated that free radicals damage the capillary basement membrane resulting in
leakage of plasma, a rise in haematocrit and aggregation of erythrocytes. Prior treatment
with allopurinol prevents these effects. Similar results were obtained from rabbit kidneys
pre-treated with the free radical scavengers SOD and catalase.l 15
Potentiation of free radical induced injury to mitochondria by prior exposure to calcium has
been demonstrated in vitro. 112 Free radical induced injury alone caused a mild increase in
mitochondrial permeability and a reduction in ATP synthesis, both of which were more
marked after prior mitochondrial loading with calcium. In addition, free radicals had no
effect on electron transport, but the combination of free radicals and calcium caused an
uncoupling of respiration.
Lipid peroxidation
Free radicals are thought to produce cellular damage through peroxidation of
polyunsaturated fatty acids in plasma membranes, resulting in increased membrane
permeability. 116,117 Increased permeability of tubule cell membranes may cause impaired
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solute transport; increased mitochondrial permeability would allow an influx of calcium; the
activity of mitochondrial ATPase and the process of oxidative phosphorylation also depend
on the phospholipid content of the mitochondrial membrane;! 18,119 increased lysosomal
permeability might release hydrolytic enzymes and cause further cell degradation.
Paller showed that ischaemia alone had no effect on lipid peroxidation, but that ischaemia
plus reflow caused an increase in the membrane lipid peroxide malondialdehyde.l 13
Presumably this is because the production of 02"' by xanthine oxidase requires the presence
ofmolecular oxygen. SOD reduced lipid peroxidation in renal cortical mitochondria.
2:1:9 The role of endothelin
In 1988 Yanagisawa et al isolated and cloned a potent vasoconstrictor secreted by
endothelial cells. 120 This substance, called endothelin (ET), was subsequently shown to be
a more potent vasoconstrictor than angiotensin, vasopressin or neuropeptide Y.
Endothelin is generated by proteolytic cleavage of a prohormone by endothelin converting
enzyme and exists in three isoforms - ET-1, ET-2, ET-3. 121,122 ET-1 is the most potent
and widely distributed of the three isoforms and in the kidney is produced by endothelial
cells, mesangial cells and tubule epithelial cells. 123-126
There are at least two endothelin receptors, ET^ and ETg, both of which are distributed
throughout the body, including the kidney. 127 The ET^ receptor promotes
vasoconstriction, cellular proliferation and matrix deposition. 128-130 The ETg receptor
appears to mediate release of vasodilalatory prostaglandins (PG) and nitric oxide
(NO). 121,132 However, there is also evidence that ETg mediates renal
vasoconstriction. 12 3
Firth and Ratcliffe (1992) showed that renal ischaemia caused an increase in prepro ET-1
expression which was present two hours after ischaemia and still present 7 days later.34
Ischaemia has been shown to increase the affinity of ET^\ and ETg receptors for ET-1 in the
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renal cortex. 135 Various injurious stimuli also appear to upregulate ET receptors -
particularly the ETg receptor. 136 This may be a physiological mechanism designed to
protect against the vasoconstricting action of endothelin by increasing production of PGI2
and NO.
ET has been shown to potentiate cellular proliferation, hypertrophy and collagen
deposition.129,130 Therefore, as well as being a causative factor in the glomerular
hypoperfusion that occurs in ARF, ET may also be involved in the long term outcome. The
development of renal scaring will of course, prevent full functional recovery from ARF.
2:1:10 The role of intercellular adhesion molecules
Leukocyte adhesion molecules have been shown to regulate the interactions of leukocytes
with other leukocytes, endothelial cells and extracellular componants.137-139 Intercellular
adhesion molecule-1 (ICAM-1) expression on endothelial cells is increased by various
mediators of inflammation. 139 jn the normal kidney ICAM-1 expression is low but it is
increased following exposure to cytokines and also in various glomerulopathies.140,141
Hypoxia followed by reflow has also been shown to increase ICAM-1 expression in cultured
endothelial cells. 142 Thus renal ischaemia, with increased levels of inflammatory
mediators, may cause increased expression of ICAM-1. The resulting leukocyte adhesion
with activation of leukocytes and release of cytokines will increase vascular permeability.
As mentioned in section 2:1:8 activated leukocytes also release free radicals which in turn
will cause further tissue damage.
Leukocyte adhesion may also result in capillary obstruction and contribute to vascular
stasis.
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2:1:11 The role of platelet activating factor
When stimulated, a number of cell types, including glomeruli and renal medullary cells, are
capable of producing platelet activating factor (PAF).' 43 Intrarenal administration of PAF
to anaesthetised dogs caused a dose dependent decrease in RBF, GFR, urine volume and
sodium excretion without any significant, systemic, haemodynamic changes. 144
Several mechanisms are involved in the ARF induced by PAF.
a. Decreased renal blood flow. PAF has a direct contractile effect on vascular smooth
muscle.145
b. A reduction in Kf. PAF can cause contraction of cultured mesangial cells and has also
been shown to reduce Kf in vivo. 146,147
c. In isolated rat or rabbit kidneys, PAF has been shown to increase the production of
thromboxane B2, a potent vasoconstrictor. 146,148 paf antagonists can block the PAF
induced release of thromboxane B2 from cultured rat and human mesangial cells. 149
d. PAF induces neutrophil aggregation and activation. 150 This results in the generation
and release of free radicals which can cause tissue damage.
2:2 Modification of acute renal failure
2:2:1 Mannitol
Mannitol is a simple sugar, molecular weight 182 daltons. When given intravenously it is
not metabolised, but is freely filtered by the glomeruli into the tubular fluid where it acts as
an osmotic diuretic. In healthy individuals intravenous mannitol results in a profound
diuresis and natriuresis. There are six theoretical reasons, based on animal studies, why
mannitol might ameliorate ARF.
a. Intratubular casts may be flushed out by an increase in tubule flow rate. Morris et al
(1972) showed that glomerular filtration and urine flow continued in rats infused with
hypertonic mannitol during progressive reduction in renal perfusion pressure produced by
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aortic clamping. 151 in hydropenic rats or rats infused with isotonic saline alone,
glomerular filtration was abolished. Mannitol infused acutely after the perfusion pressure
had been lowered to 40mm Hg in hydropenic rats restored urine flow and glomerular
filtration.
b. The same workers also demonstrated an increase in renal blood flow (RBF) after
mannitol in rats subjected to partial renal artery occlusion. Isotonic saline was
ineffective. 151 The increase in RBF preceded the increase in urine flow rate and was
assumed to be due to a decrease in afferent arteriolar resistance.
c. By reducing hypoxic cell swelling, mannitol may limit vascular congestion and prevent
the no-reflow phenomenon after hypoxia. Flores et al (1972) in a classic study
demonstrated the ability of hypertonic mannitol to reverse the no-reflow phenomenon seen
after complete renal artery occlusion in rats. 152 Equivalent expansion of the extracellular
fluid volume with isotonic saline or isotonic mannitol had no effect.
d. Mannitol causes plasma volume expansion which reduces the haematocrit.
Haemodilution appears to protect against erythrocyte aggregation following an ischaemic
insult. 153
e. Mannitol may protect mitochondrial function after ischaemia. Schrier and colleagues
(1984) demonstrated that in dogs with norepinepherine induced renal failure, pre-treatment
with mannitol preserved renal cortical mitochondrial function. 154 During reflow following
ischaemia the rise in intracellular calcium is buffered by mitochondria at the expense of
mitochondrial respiration. Mannitol appears to attenuate this rise in intramitochondrial
calcium thereby preventing the decrease in mitochondrial respiration. 154,155
f. Mannitol has free radical scavenging properties and may help to mop up free radical
species generated during reflow after ischaemia. 1' 5
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Can mannitolpreventARF ifgiven with intravenousfluids to high riskpatients?
In a wide variety of animal models of ARF pre-treatment with mannitol does appear to
prevent oliguria and attenuate the severity of renal dysfunction. 57,156,157 in clinical
studies the results are not so definitive. The use of prophylactic mannitol has been
promoted in certain high risk groups - vascular surgery, cardiac surgery, obstructive
jaundice and rhabdomyolysis.
a. Vascular Surgery
In 1961 Barry reported a diuresis with mannitol in four patients undergoing aortic cross-
clamping for abdominal aortic aneurysm repair. 158 jn two patients mannitol was given for
post operative oliguric and in two it was given as pre-operative prophylaxis. Although
apparently successful, these four patients are simple anecdotes. In a follow-up controlled
study the same group showed that patients given mannitol during aneurysmectomy had a
higher urine flow rate during the period of aortic cross clamping and post operatively,
compared to the controls who did not receive mannitol. 159
In a prospective study Beall et al (1963) looked at 30 patients undergoing elective repair of
an abdominal aortic aneurysm, in whom the aorta was cross clamped below the origin of the
renal arteries. 160 Patients were divided into three groups. Group 1 received standard care
with no intravenous (IV) fluid preoperatively; group 2 received adequate hydration with 5%
dextrose while group 3 received IV dextrose plus pre-operative and post-operative mannitol
as required to keep the urine output > 60ml/min. The control group showed only minimal
depression of renal function in the post-operative period although urine flow rate fell from
5.8 to 0.8ml/min. There was no change in renal function in either the hydrated group or the
group receiving fluids plus mannitol. In both groups urine output fell compared to pre¬
operative values. The post-operative urine output was not significantly different between
the two groups, although intra-operative urine flow rate was better in the mannitol group.
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This suggests that the prophylactic use of mannitol had no additional benefit over adequate
pre-operative hydration in abdominal aortic aneurysm surgery. Finally, in 1964, Powers et
al published observations on 50 high risk surgical patients who appeared to benefit from
prophylactic mannitol. 161 in addition 52 post-operative patients with established oliguria
also received mannitol. The authors comment that all 104 patients had a diuresis and that no
patient developed "acute tubular degeneration".
No further studies have been published recently. However, the use of prophylactic mannitol
and IV fluids has become standard practice in many vascular surgical units. Prospective,
controlled studies to evaluate a specific role for mannitol as compared to adequate volume
expansion alone seem unlikely.
b. Cardiac Surgery
In 1964 Berman et al studied 27 patients undergoing a mixture of aortic and cardiac
procedures. 162 Patients receiving mannitol had a higher urine output than controls.
However, mannitol did not prevent a drop in GFR which fell to approximately 50% of pre¬
operative values in both the mannitol and the control groups.
These results were confirmed the following year by Etheredge et al. 163 They studied 18
patients before and after cardiopulmonary bypass surgery. Intravenous mannitol was
associated with a diuresis but did not prevent the fall in GFR which occurred during
cardiopulmonary bypass. Unfortunately this study was uncontrolled.
In 1972 a retrospective study of 428 patients undergoing open heart surgery showed that the
incidence of severe (serum urea > 130mg/dl) or mild (serum urea 80-130mg/dl) renal failure
was 4.7% and 26% respectively. 164 Frusemide and mannitol, either singly or in
combination, did not appear to prevent this deterioration in renal function. No comment
was made about the effect on urine volume. Once again this was an uncontrolled study and
was retrospective.
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Most recently, in 1984, a prospective controlled study of children undergoing
cardiopulmonary bypass has been reported by Rigden et al in which a beneficial effect of
mannitol on post-operative renal function was found. 165 They studied 20 patients who
received 0.5mg/kg of 20% mannitol and 20 patients who received an equal volume of
Hartmann's solution. The serum creatinine rose in both groups post-operatively. Pre¬
operative values were regained more rapidly by the mannitol group, with a significant
difference between the two groups on post-operative days 3 and 5. Interestingly, the group
receiving mannitol also had less albuminuria post operatively.
c. Obstructive Jaundice
It is generally believed that obstructive jaundice can predispose to acute post-operative renal
failure. 166-168 in 1950 in a study of 350 patients with obstructive jaundice Williams et al
described uraemia as the commonest cause of post-operative death. 169 Dawson et al (1965)
found a strong correlation between the pre-operative serum bilirubin concentration and the
fall in post-operative creatinine clearance. 170 Administration of mannitol pre-operatively
reduced this fall to 18%, compared with a fall of 63% in jaundiced patients not given
mannitol.
The pre-operative administration
of mannitol and IV fluid has thus become virtually mandatory in surgery on patients with
hepatic problems. A different view, however, has been expressed by Gubern and colleagues
in 1988.1^1 They carried out a prospective, randomly allocated study assessing the effect
of mannitol on serum creatinine, creatinine clearance and urinary sodium excretion
immediately before and for three days after elective biliary tract surgery. The mannitol
group received 50g over 1 hour IV prior to anaesthesia and continued this each day for two
days after surgery. An initial loading dose of 1 litre of 5% dextrose was given to all patients
prior to surgery. Fluid balance was carefully maintained perioperatively in all patients.
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Under these circumstances, there was no significant change in creatinine clearance in the
control group (mean pre-operative creatinine clearance 64ml/min; post-operative
54ml/min). Surprisingly there was no beneficial effect of pre-treatment with mannitol on
post-operative renal function. Indeed patients whose creatinine clearance exceeded
70mls/min pre-operatively had a statistically significant fall in this post-operatively despite
mannitol infusion. The authors conclude that "The routine use of an osmotic diuretic is of
no value in preventing renal failure in patients undergoing surgery for the relief of
jaundice".
d. Rhabdomyolysis
Animal models of rhabdomyolysis have shown that prophylactic use of mannitol may
prevent renal dysfunction by inducing a diuresis and so preventing intratubule obstruction
with casts. 172 However, in a clinical setting the prophylactic use of mannitol is rarely
possible. Early treatment of rhabdomyolysis with a forced alkaline diuresis and mannitol
may prevent or attenuate renal dysfunction. Ron et al (1984) began an alkaline solute
diuresis in seven patients with extensive crush injuries immediately after extraction from the
debris. 173 None of these patients developed renal failure. This is a case report without any
controls, and there are no studies comparing the effect of mannitol versus adequate fluid
replacement alone.
Can mannitol convert oliguric ARF to polyuric ARF?
The concept that a mannitol infusion given during the phase of pre-renal failure known to
precede acute established organ failure might produce polyuria and prevent progression of
renal failure was first made by Barry and colleagues in 1962.174 Sixteen of 24 patients
with prolonged oliguria, low urinary specific gravity and a tentative diagnosis of ARF
developed polyuria (urine flow > 60ml/hour) after acute intravenous infusion of mannitol.
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Three patients responded to a single dose of 12.5g. The remainder required a mannitol
infusion titrated to maintain adequate urine volumes. They felt unable to predict which
patients would respond to mannitol and made the plea that it be initiated "the moment
oliguria is confirmed, even coincident with resuscitation and in dehydrated patients, since
the moderate urinary fluid loss required by improved renal haemodynamics and function
can be replaced easily. No patient should be denied a trial".
These observations were strengthened by the studies of Eliahou.175 Ten patients diagnosed
as having "incipient" ARF on the basis of oliguria and "low" urinary osmolality diuresed
after 250ml of 10% mannitol intravenously. Renal function returned to normal generally
within 2-4 days. Unfortunately, this study, as with all others, was not controlled for volume
expansion alone. In an attempt to predict which patients with incipient ARF might respond
to mannitol, the Glasgow group reported clinical observations on a total of 72
patients. 176,177 All patients were oliguric (urine flow < 20-30ml/hour) and had a low
urine to plasma urea and osmolality ratio. Care was taken to ensure that obvious volume
depletion was corrected by the use of intravenous blood, plasma or electrolyte containing
fluid. However, central venous pressure was measured in only 4 patients. No information
was available on oxygen delivery or blood pressure at the time of mannitol administration.
Forty five of the 72 patients experienced a significant increase in urine volume and
amelioration of their ARF after mannitol (20-60gm over 6 hours). It was concluded that a
response to mannitol should be expected when the urine:plasma osmolality > 1.05, the
duration of oliguria <50 hours and persistent peripheral circulatory failure is absent.
Once again this study was uncontrolled. The effect of continued volume expansion per se in
these patients is unknown.
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Can mannitol improve GFR andARF?
A rise in creatinine clearance of, on average 24 ± 3ml/min is shown by Valdes et al in 1979
in 7 ventilator dependant patients after 100ml of 20% mannitol intravenously. 178 However,
all patients had good pre mannitol urine volumes (90 ± 22ml/hr); only 2 patients had urine
volumes < 50ml/hr, and pre mannitol renal function was only mildly impaired (creatinine
clearance 91 ± 27ml/min). Urine osmolality was low in only 1 patient, implying that renal
failure was not established and the patients were probably primarily dry.
In summary, while there is much anecdotal evidence in favour of a beneficial role for
mannitol, there are no prospective randomly allocated studies in which its effect are
compared with those of volume expansion alone. Until such studies are carried out, the case
for mannitol must remain, in the words of the Scottish legal verdict, "Not proven".
2:2:2 Loop Diuretics
There are six "loop diuretics" currently available or under investigation in the United
Kingdom (Mersalyl, ethacrynic acid, frusemide, bumetanide, piretanide and torasemide).
Frusemide and its successors all have a similar principal mode of action. The diuretic effect
is due to their ability to bind to and inhibit the Na+/2C1/K+ transporter in the luminal
membrane of the thick ascending limb of Henle - hence the expression "loop diuretic"
(Figure 2:1). 179 The blocked uptake of chloride leads to a fall in cytosolic chloride activity
and inhibition of short circuit currents. Na/K ATPase activity at the baso-lateral membrane
becomes unnecessary as a result of the blocked sodium uptake. The cell enters a "resting
state" with no need to expend energy and consume oxygen.
Thus far, frusemide has been the principle loop diuretic studied in ARF. Studies in animal
models of ARF have given us several theoretical reasons as to why these diuretics might be
of benefit.
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a. Loop diuretics produce a "resting state" in cells of the thick ascending limb of Henle as
described above. In isolated perfused kidneys and in rats, frusemide has been shown to
preserve tissue ATP levels, presumably by suppressing reabsorptive work. As a
consequence, cells of the thick ascending limb - those areas farthest from oxygen supply -
are protected from hypoxic damage.53,54
b. Loop diuretics will increase tubule flow rate. This may flush out intratubular casts and
help to prevent intratubular obstruction.
c. Loop diuretics, by inhibiting chloride flux at the macula densa, will inhibit
tubuloglomerular feedback. Hence the effects of increased sodium delivery to the macula
densa resulting from proximal tubule damage will not in turn cause a fall in nephron
filtration rate. This will protect GFR. 180
d. Loop diuretics reduce renal vascular resistance and increase RBF.181 The exact
mechanism is unknown. Inhibition of prostaglandin dehydrogenase, a recognised effective
of loop diuretics may be important. 182 Prostaglandin dehydrogenase degrades PGE2, a
substance known to cause afferent arteriole dilatation. Prostaglandin synthetase inhibitors
reduce the vasodilatory effect of loop diuretics. 183
Do loop diuretics convert oliguric renalfailure to polyuric renalfailure?
Controversy exists over the answer to this question. In an uncontrolled, retrospective
analysis, Minuth and colleagues could not demonstrate a response in 51 of 79 patients
(64%) given loop diuretic after the onset of ARF.184 140/,, hacj a transient diuresis and
required repeated doses of frusemide, and 22% developed a sustained diuresis after a single
dose of loop diuretic. In agreement with Minuth, Kleinknecht could not show any
significant reduction in the duration of oliguria following intravenous loop diuretic. 185
Others have shown that administration of frusemide either as a bolus or as a continuous
infusion, can promote polyuria. 186-192
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Do loop diuretics shorten the period of renal dysfunction and reduce the need for
dialysis?
In 1971 Cantarovich showed that dialysis dependent patients receiving a progressive dose of
frusemide (100 - 3200mg/day in geometric progression) had a smaller duration of
creatinaemia than patients receiving a fixed dose of frusemide (600mg/24hours) or those
receiving conventional therapy (17.5 days, 25.4 days and 26.6 days respectively). 186
Patients in the fixed dose group were given frusemide 600mg daily for 14 days, while the
progressive dose group had 1240mg daily for 7 days. Therefore, the size of the dose
appears to be more important than the total dose of drug given.
In a second study, the same group showed that 2000mg frusemide given on alternate days to
dialysis dependent patients decreased the number of dialyses required, but not the time
taken to recover a normal creatinine. 187 However, the patients in this study were compared
with retrospective controls.
Minuth et al also demonstrated that patients who responded to frusemide had a significantly
lower need for dialysis than those who failed to respond. 184 This was again a retrospective
analysis of case sheets, and the dose of frusemide varied between 40mg and 500mg daily.
Despite an increase in urine output in patients receiving frusemide, Brown et al could not
demonstrate a rise in GFR sufficient to decrease the need for dialysis. 190 Kleinknecht et al
did a prospective analysis of 66 patients. 185 They could not show any difference in the
number of dialyses or the time to reach a spontaneous decrease in the blood urea between
treated and control patients. No severity of illness score was performed, but the two groups
did not appear to differ.
Do loop diuretics lower mortality?
No! Many studies have addressed this question.184-186,188,191 Only one, that of
Anderson et al, showed any improvement in mortality. 191 In this study, a group of
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nonoliguric patients (spontaneously nonoliguric and pharmacologically induced
nonoliguric) had a lower mortality than a group of oliguric patients (26% v 50%). However,
spontaneously nonoliguric patients had a lower fractional excretion of sodium (FENa) than
oliguric patients. Oliguric patients who responded to frusemide had a milder degree of renal
impairment as evidenced by lower serum creatinine, lower urine sodium and lower FENa
than those who did not respond. Thus the nonoliguric patients who had a better mortality
also had less severe renal failure. No severity of illness score was performed to determine if
the non- oliguric group was indeed less sick than the oliguric group.
While mortality is an outcome of particular interest it is a difficult question to address in
studies examining the effect of various treatment regimens in ARF. Choosing endpoints
which allow assessment of renal function such as duration of renal failure, need for dialysis
etc are specific. Mortality is not an end point specific to ARF and may be affected by many
other factors during the course of the patient's illness. It is well recognised that many
patients with ARF die not from ARF, but from the primary illness. Mortality may therefore
not be an appropriate endpoint to address when assessing the effect that loop diuretics have
on recovery from ARF, although shortening the period of renal dysfunction may have a
beneficial effect on prognosis.
However, as a key factor in patient outcome, mortality has been looked at in all studies
addressing the role of loop diuretics in ARF. As in the majority of these studies loop
diuretics have very little effect other than to increase urine output, it is not surprising that no
beneficial effect on mortality has been shown. Anderson's study compares non-oliguric
with oliguric patients but as there were patients on frusemide in both groups no comment




In normal subjects, low dose dopamine (1-5 pg/kg body wt/min) causes a rise in renal
plasma flow, increased inulin clearance and increased FENa.193 jhe prophylactic use of
low dose dopamine in at risk patients has been shown to reduce the incidence of
postoperative ARF.194,195 Salem et al (1988) showed that aortic cross clamping reduced
GFR, which was restored or increased by the addition of dopamine. 195 Schwartz et al
(1988) demonstrated a rise in renal blood flow that was not associated with a significant
diuresis, in patients undergoing vascular surgery who received dopamine either pre or post
operatively.196
In oliguric, euvolaemic intensive care patients, low dose dopamine alone caused an increase
in urine volume which fell when the dopamine was stopped. The response to dopamine was
independent of serum creatinine. 197 Parker et al demonstrated an increase in osmolar
clearance, FENa, creatinine clearance and urine volume in 52 patients on low dose
dopamine. 198 This study was not controlled and eighteen of the patients with a creatinine
clearance of 13+9.9ml/min required a frusemide infusion to increase urine volume. The
increase in creatinine clearance was not significant in the patients requiring frusemide.
Three separate groups have shown that patients who remain oliguric despite high dose loop
diuretics or hypertonic mannitol, may begin to diurese if dopamine is added. 199-201 Again
none of these studies were controlled. Plasma frusemide levels may have been high at the
time of dopamine administration and could have contributed to the diuresis observed after
the dopamine infusion.
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2:2:4 Atrial natriuretic peptide
"...the most promise for an ANP-related drug is in the treatment of acute renal failure."
Pollock and Opgenorth 202
Animal studies have shown that an intravenous or an intrarenal arterial infusion of atrial
natriuretic peptide (ANP) or a residue peptide, atriopeptin III (APIII), can reverse the effects
of experimental ischaemic ARF.202,203 -phe mechanism by which this occurs is thought to
be due to the vasodilatory action of ANP. Schafferhans et al showed that immediate
infusion of intrarenal arterial ANP after a 40 minute intrarenal arterial noradrenalin infusion
caused an increase in GFR, urine flow and FENa and thus reversed the ischaemic effect of
noradrenalin.204 Shaw et al (1987) induced ischaemia by renal artery occlusion and then
infused ANP into the renal artery.205 Creatinine clearance 4 hours and 24 hours post
infusion fell in control rats, but was within the normal range for rats infused with ANP.
Rats given ANP also had a greater urine volume than controls at 4 hours and a lower FENa
at both 4 and 24 hours. This group also showed that morphological damage was less after a
4 hour infusion ofANP.
Intravenous administration of Atriopeptin III has also been shown to improve GFR, urine
flow and tubule function in both in vitro and in vivo studies when given after renal artery
occlusion.206 This study also showed that post ischaemic renal ATP regeneration improved
after ANP infusion.
Conger et al (1991) induced renal failure in rats with a norepinephrine infusion.203 Two
days later, when ARF was established, an infusion of APIII plus dopamine (APIII-D) to
maintain blood pressure was commenced over a four hour period. At the start of the
infusion, serum creatinine had increased in both control and study groups to 1,65+0.6mg/dl
and 2.02+0.99mg/dl respectively. At day four, control rats infused with saline had a serum
creatinine of 2.78+2.1 lmg/dl and rats infused with APIII-D had a serum creatinine of
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1.21+0.8 lmg/dl (p<0.05). Rats treated with APIII-D also had a lower FENa at day four. In
other words, in animal studies APIII-D causes a sustained improvement in GFR and tubule
function in established ARF.
Reduced size analogues of ANP have also similar effects in rats with ischaemic ARF.
Pollock et al (1992) showed that a short term intravenous infusion of a reduced size
analogue of ANP attenuated the histological damage and the rise in creatinine induced by
bilateral renal artery occlusion.202
Human studies are limited. Gotz et al (1989) studied 13 patients with dopamine and
frusemide resistant ARF.207 Seven oliguric and six nonoliguric patients were given ANP
2.5ug/min for 3 hours. There was no change in urine volume, GFR or FENa in the oliguric
patients. In the nonoliguric patients urine flow increased more than 50% and FENa
increased by about 40%. There was no change in GFR. It is likely that the nonoliguric
group who responded to ANP had less severe renal failure than the oliguric group. The
nonoliguric group had a higher pre study GFR compared to the nonresponders
(19.8+8.5ml/min v 6.2+1,5ml/min).
Recently, Rahman et (1994) studied 53 patients with established, intrinsic ARF.208
Patients were allocated to one of 2 groups. Group 1 received intrarenal ANP via catheters in
both renal arteries for 8 hours, or intravenous ANP for 24 hours. Some patients also
received mannitol or frusemide. Patients in group 2 received mannitol, frusemide or no
diuretic and were not given ANP.
Urine flow increased significantly in both groups in the first 8 hours of treatment, while
creatinine clearance increased significantly in group 1 only. Significantly fewer patients in
the ANP group required dialysis compared to group 2 (23% v 52%, p<0.05), But there was
no significant difference in survival, although there was a trend towards improved survival
in group 1. Interestingly, Rahman points out in his discussion that although '...there was no
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convincing evidence that diuretic therapy was of proven benefit in ARF patients, most
primary physicians indicated they were reluctant to enter patients if they were randomised
to a group that would not at least receive diuretic therapy'.
Two other studies failed to show any consistent benefit from the use of ANP in the post
transplant patient.^09,210 However, ANP may offer protection against post transplant ARF
if added to the perfusate at the time of harvesting the kidneys.
There are two major problems which limit the clinical use of ANP. Atrial peptides act by
peripheral vasodilataion and in large quantities cause hypotension. Endogenous and
exogenous ANP are rapidly degraded by neutral endopeptidase. The development of oral
enzyme inhibitors of ANP degradation may be one way of ameliorating the development of
ARF in the future.
2:2:5 Calcium channel blockers
If the vascular consequences of an ischaemic insult, ie increased renal vascular resistance,
loss of autoregulation, hypersensitivity to renal nerve stimulation and decreased glomerular
permeability, are due to an increase in intracellular calcium in afferent arteriolar and
glomerular mesangial cells, then the administration of a calcium channel blocker might be
expected to attenuate or abolish these effects.
Burke and colleagues showed that an intrarenal infusion of verapamil, given for 30 minutes
before renal ischaemia was induced by intrarenal noradrenalin (NA), had a protective effect
on both function and morphology.211 Verapamil or nifedipine given intrarenally for 2
hours after an intrarenal NA infusion also protected the kidney.211 The protection afforded
by verapamil in a renal artery clamp model of ARF is not so conclusive.212 These authors
suggest that verapamil may prevent complete cessation of renal blood flow in the NA
model.
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The concentration ofNA, vasopressin and angiotensin are increased in ARF. Verapamil and
nifedipine have been shown to block the response of the arterial resistance vessels to these
vasoconstrictors.213 it has been shown that these vasoconstrictors act on vascular smooth
muscle and mesangial cells by causing an increase in cytosolic calcium.213-217
The effect of calcium channel blockers on renal tubular epithelium is less certain. Calcium
channels have not yet been demonstrated in renal tubule cells. However, verapamil has
been shown to reduce the uptake of calcium seen in proximal tubules after 30 minutes of
anoxia.218
Calcium channel blockers seem to be effective when administered prior to or immediately
after the ischaemic insult. Their potential may therefore be more fully utilised in renal
transplantation. Experimental studies in both animals and humans have shown that this
class of drug does indeed have a beneficial effect in renal transplantation. Isolated rat
kidneys flushed with verapamil or emopamil had higher inulin clearances and renal cortical
ATP levels than controls.^ 19,220 jn clinical studies Duggan showed that verapamil given
to donors before harvesting the kidneys improved early graft function.221 Early rejection
was also reduced. Pre treatment of renal grafts and recipients with diltiazem also reduced
the incidence of delayed graft function.222,223 in this study graft survival was not affected.
2:2:6 Other potential therapeutic agents in acute renal failure
Adenosine nucleotides and magnesium chloride infused into rats after an ischaemic injury
accelerated recovery of inulin clearance and tubule function, and also preserved cell
morphology.224,225 ATP given alone causes adverse cardiovascular effects by chelating
divalent cations. Equimolar amounts of magnesium chloride given with ATP prevent these
adverse effects from occuring.226 As yet there are no human studies looking at the effect of
magnesium chloride and ATP in ARF.
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Thyroxine stimulates renal tubule transport mechanisms and has been studied in ARF in
animals and man with encouraging results.227,228 Unfortunately the clinical study was
uncontrolled.228 Glucagon has beneficial effects if given prior to or immediately after
development of ARF, but has no effect on established ARF and is therefore of no
therapeutic value, although it may yet have a role in prophylaxis against ARF.229
2:3 The future
There have been exciting developments in our understanding of the pathogenesis of acute
renal failure which may well contribute to our ability to modify the disease. Evidence for
the role of endothelin is accumulating. Tomita et al (1989) have shown that plasma
endothelin levels in patients with ARF are raised, while in experimental studies antibodies
to endothelin have improved the outcome of ARF.230,231 Gellai et al (1994) showed that
in rats with established ARF, infusion of a selective endothelin receptor antagonist (BQ123)
improved Na+ reabsorption and moderately increased GFR and K+ excretion.232 mil
vehicle treated rats died by day 3, whereas rats given the endothelium receptor antagonist
were all alive at day 4 and eventually 75% fully recovered. The therapeutic potential for
this in established ARF is enormous.
A monoclonal antibody against intercellular adhesion molecule 1 (anti-ICAM-1) improved
post ischaemic ARF when given up to 2 hours after the ischaemic insult.233 Histological
evidence of ARF and tissue levels of myeloperoxidase (induced by ischaemia) were both
significantly reduced by anti ICAM-1 infusion.
ANP is thought to exert its biological actions by activating guanylate cyclase thus increasing
the production of cyclic guanosine monophosphate (cGMP). Therefore, inhibiting the
degradation of cGMP would be expected to have a similar effect as administration of ANP.
Guan et al induced ARF in rats by clamping the renal arteries for 15 minutes.234 Twenty-
four hours later the rats were given vehicle, ANP or Zaprinest - a cGMP specific
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phosphodiesterase inhibitor. Rats given Zaprinest had a significantly greater GFR 24 hours
after infusion of the drug. Rats given ANP also had an increased GFR but this did not reach
statistical significance.
Urodilatin is another natriuretic peptide whose structure comprises the entire sequence of
human ANP plus a four amino-acid N-terminal extension.235 it is detectable in human
urine but not plasma.236 Unlike ANP, its hypotensive effect is minimal, but it causes a
greater increase in GFR and more of a natriuresis than ANP.237
In an animal model of ischaemic ARF, Shaw et al demonstrated that urodilatin and
dopamine had a greater beneficial effect on GFR than dopamine alone or dopamine plus
nitroprusside.238 jn a recent randomised controlled trial in which patients had developed
oliguria following cardiac surgery, Wiebe et al showed that an infusion of urodilatin caused
a brisk diuresis - 363.6 ± 102ml/hr v 69.4 ± 20ml/hr in the control group.239 g^o/0 Gf
control group required dialysis whereas none of the patients who received urodilatin
required dialysis.
Several authors have shown that pre treatment with a PAF receptor antagonist improves the
recovery of the GFR after acute ischaemic renal injury.240-242 \s ygj there are no studies
examining the effect of PAF receptor antagonists given after the acute ischaemic insult.
Aggregation of detached tubule epithelial cells causes intratubule obstruction and
contributes to the maintenance of ARF. Integrins recognising the argenine-glycine-aspartic
acid (RGD) sequence may participate in cell-cell adhesion of exfoliated tubule cells and
could thus be targeted to prevent tubule obstruction.243 jn vjtro studies have demonstrated
that synthetic RGD peptides that mimic the RGD sequence of integrin ligands inhibit cell-
cell adhesion of tubule epithelial cells. In rats with experimental ARF, RGD peptides given
at the time of reperfusion accelerate recovery from ARF.244
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The number of potential therapeutic agents in ARF currently under investigation reflects the
extremely complex and multifactorial nature of the pathogenesis of ARF (Figure 2:2). The
existence of many pathways (some interrelated) all ultimately resulting in tubule cell death
means that a single therapeutic agent targeting a particular pathway is probably not the
answer. In addition, most of the therapeutic agents show a beneficial effect when given
prior to or immediately after reflow. In clinical practice this is rarely possible and therefore
attention must be turned to hastening regeneration of tubule cells and thus recovery from
ARF.
Growth factors are polypeptides that can stimulate or inhibit cell proliferation. In rats with
experimental ARF induced by bilateral renal artery clamping, exogenously administered
epidermal growth factor (EGF) attenuated the rise in serum creatinine and increased renal
DNA synthesis.245,246 Binding of EGF in the kidney was increased.
Insulin like growth factor-1 (IGF-1) is mitogenic for renal epithelial cells and in ARF there
is an increase in the number of IGF-1 receptors in regenerating tubules.247 However, IGF-
1 appears to be important in differentiation and maturation of regenerating cells as the
increase in IGF-1 appears after proliferation has occurred. Recombinant IGF-1 given to rats
5-24 hours after induction of ischaemic ARF caused accelerated regeneration and repair of
the epithelium and attenuation of ARF.248,249 when given prior to the ischaemic insult
there did not appear to be any additional benefit.249
Hepatocyte growth factor (HGF) is also mitogenic to a variety of cultured proximal and
distal tubule epithelial cell lines.250 Human recombinant HGF given intravenously to mice
with HgCl2 induced ARF caused a significant increase in DNA synthesis in tubule cells in
the outer medulla where an increase in HGF receptor mRNA was also detected.251 ln rats
with ischaemic ARF, subcutaneous recombinant human HGF given 30 minutes after
reperfusion enhanced recovery and improved survival.252
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Other growth factors may also have a role in the process of repair following ARF.
Transforming growth factor-|3 (TGF-P) effects a different physiological response in
different cell types. It inhibits epithelial cell proliferation; mesenchymal and endothelial
cell mitogenesis can be stimulated or inhibited.253 Therefore TGF-P may regulate the
regenerative response. Fibroblast growth factors are potent inducers of blood vessel growth,
and induce expression of proteolytic enzymes involved in tissue remodelling.253 Their role
in regeneration after renal cell injury is not clear. Similarly, the role of platelet derived
growth factor like protein (PDGF) released by mesangial cells (which also express PDGF
receptors) is not clear.254 Endothelial and mesangial cells have a proliferative response to
PDGF, but PDGF does not appear to be mitogenic for renal epithelial cells in culture.253
Some growth factors seem to have a beneficial effect on each other. IGF-1 and EGF
reciprocally enhance the expression of their receptors. Thus a combination of growth
factors given post insult may result in a more effective mitogenic response.255
2:4 Summary
The pathogenesis of ischaemic ARF is extremely complex with a number of factors
contributing to the development and progression of ARF (Figure 2:2). There have been
many therapeutic attempts to modify the progression of ARF and to date none have proven
clinically useful. The role of loop diuretics has been investigated in the past but the studies
performed were poorly controlled, retrospective or anecdotal. There is a need therefore for
a properly controlled, prospective double blind study of the effect of loop diuretics in ARF.
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Figure 2:1 Action of loop diuretics in the thick ascending limb ofHenle's loop
* Bold arrow indicates site of action of loop diuretics at the Na+K+Cl~ transporter
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Figure 2:2 Factors contributing to the development and progression ofARF
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3 Energy Expenditure and Outcome in Acute Renal
Failure
3:1 Daily energy expenditure
Total daily energy expenditure (EE) is made up from the following components: basal
metabolic rate (BMR), resting energy expenditure (REE), dietary thermogenesis, shivering
and non shivering thermogenesis, and voluntary physical activity.
The BMR was defined in 1920 by Boothby and Sandiford as "...the minimal heat production
of an organism, measured from twelve to eighteen hours after the ingestion of food and with
the organism at complete muscular rest".256 The BMR is a result of the metabolic
processes required for cellular integrity, and also the metabolic processes of various organs
required to maintain life. The BMR is related to cell mass and can therefore be predicted
from variables such as height, weight and body surface area (BSA) corrected for age and
sex.257 The regulation of BMR is largely by changes in peripheral metabolism of thyroid
hormone.258
3:2 Effect of illness on basal metabolic rate
The BMR is measured in a resting subject in a thermoneutral environment 12-18 hours
after last eating. Injury, burns and sepsis all cause an increase in core temperature and
BMR. The regulation of EE in trauma and sepsis appears to be similar to that of non
shivering thermogenesis and is activated by the sympathetic nervous system.257 As well as
increased heat production in brown adipose tissue there is a resetting of the hypothalamic
'thermostat' to maintain a higher core temperature. Thus the patient feels cold resulting in
shivering and non shivering thermogenesis with a rise in the core temperature until it meets
the new set point. During the process energy expenditure is increased.
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Burns cause an obligatory loss of heat from the surface of the burn because blood flow to
regenerating granulation tissue is high and not regulated by the autonomic nervous
system.259 Therefore the temperature at the skin surface remains close to the core
temperature and heat is lost by radiation, conduction and convection (dry heat loss) and
evaporation (wet heat loss). In this instance heat loss and therefore EE can be minimised by
keeping the patient in a warm, humid environment.
Trauma and sepsis also cause an imbalance in the glucose-fatty acid cycle with marked
hyperglycaemia, even although energy is largely derived from oxidation of fat.260 This is
due to the high concentration of hormones associated with increased sympathetic activity
such as glucagon, Cortisol and catecholamines. During an infusion of total parenteral
nutrition (TPN) there is an increase in noradrenalin excretion with an increase in EE.257
Thus diet induced thermogenesis from overfeeding results in metabolic stress.
3:3 Resting energy expenditure
REE may be measured at any time of day, as long as the methods outlined in chapter seven
are adhered to, and has been shown to be approximately 10% higher than the basal energy
expenditure as measured in deep sleep.261-263 accounts for 75-90% of total energy
expenditure; diet induced thermogenesis, shivering and non shivering thermogenesis, and
exercise make up the rest.257,264
A number of factors affect the REE:
1. Size of the individual - REE increases with increased height and weight.261
2. Sex - males have a higher REE than females of the same weight. REE correlates closely
with lean body mass and males have a higher lean body mass compared to females.261
3. Age - older patients have a reduced REE.261
4. Diet - intermittent feeding causes an increase in REE of 8-10% whereas continuous
enteral or parenteral feeding reduces diet induced thermogenesis by 4-8%.265
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Thermogenesis peaks within the first hour after a light meal and has been shown to
return to baseline within the next hour.262 Hypercaloric parenteral nutrition increases
metabolic rate but the effect is stable when the nutrients are infused at a constant rate.263
5. Sleep - REE is reduced during sleep.266
6. Work of breathing - impending respiratory failure causes an increase in REE.264
7. Disease - release of neurotransmitters, mediators of inflammation, increased catabolism,
increased core temperature all increase REE.265 xhjs effect is not seen until the patient
has passed from the ebb phase to the flow phase of injury, usually 8-12 hours after the
onset of acute injury.267
8. Physical activity causes a rise in REE.268,269
9. Body temperature - each degree rise on the Farenheit scale causes a 7% rise in REE
(13% rise for each degree on the Celsius scale).264
10. Drugs also affect the REE. Pressor agents and catecholamines increase REE while
narcotic analgesics, sedatives, general anaesthesia, beta blockers and alpha blockers all
cause a reduction in REE.269-271
The REE can be predicted using the Harris-Benedict equation (HBREE).272 -ppis js dealt
with in detail in chapter 7.
3:4 Measurement of EE
Indirect calorimetry provides a method of accurately measuring EE at the bedside.262 a
full description of the technique is given in chapter 7. Its main use has been in the design of
nutritional regimens suitable for different disease and organ failure states.264
The ratio of REE measured using indirect calorimetry to the predicted REE (REE/HBREE)
can be used to determine whether patients are hypermetabolic (ratio >110%),
normometabolic (ratio >90%, <110%) or hypometabolic (ratio <90%).264
3-3
3:5 Energy expenditure in acute renal failure
Overall mortality from ARF remains high.273 However, mortality from various types of
ARF is variable ranging from 35% (nephrotoxic ARF) to 75% (ARF associated with sepsis
and MOF).274,275 jt [ias been suggested that the difference in mortality between different
types ofARF is due to differences in metabolic status.276 Hypermetabolism in ARF results
in malnutrition, impaired wound healing and impaired immunological function with
increased morbidity and mortality.277
EE in ARF has been reported to vary between 1.19 - 2.5 times the predicted REE.278-280
In the study from Bouffard et al the measurements of EE were widely scattered implying
that ARF is not associated with a predictable increase in EE.278 jiie presence of sepsis did
however, significantly increase EE.
The APACHE II score is a marker of physiological stress and, when measured within the
first 24 hours of hospital admission, can be used to predict outcome.281 It is possible,
therefore, that the APACHE II score may be related to the REE of the patient.
3:6 Summary
Various disease states cause an increase in REE and in general, the more severe the injury
the greater the metabolic response.269
Indirect calorimetry is an accurate way of measuring energy expenditure in the critically ill
patient, which in turn can be used as a marker of physiological stress. Chapter 7 (Resting
Energy Expenditure and the APACHE II Score in Patients with Acute Renal Failure)
describes studies which I carried out on patients with ARF. The REE was measured and
compared with another objective marker of physiological stress (APACHE II score).281
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4 Aims and Objectives
The multifactorial pathogenesis of ARF makes it unlikely that a single agent will be able to
attenuate the effects of ischaemic ARF. Rather, combination therapy targeting contributory
mechanisms may be the answer. To date, the most widely used drugs in the treatment of ARF
are loop diuretics, mannitol and dopamine, but a precise role for these drugs in the clinical
setting of potential or established ARF has not been established. Available studies are usually
retrospective, poorly controlled or merely anecdotal reports.
Intracellular calcium levels have been shown to be raised in experimental ARF and also in
white cells and red cells from patients with sepsis.282-284 jt is possible therefore that
intracellular calcium levels may be raised in patients with ARF, and that the magnitude of the
rise may be related to prognosis.
Resting energy expenditure is increased in various disease states and the more severe the injury
the greater the metabolic response.267 jhe APACHE II score is a marker of physiological
stress and can predict outcome of illness.281 ]t may therefore be related to the metabolic
response to ARF as reflected in energy expenditure.
The aims of this thesis are to examine the following hypotheses:
1. Patients with ARF who are treated with high dose loop diuretics have a better prognosis in
terms of survival and speed of recovery than those who receive placebo.
2. Levels of intracellular calcium may have an effect on outcome.
3. Resting energy expenditure may affect outcome.
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The specific objectives of the studies are as follows:
1. Describe the role / usefulness of loop diuretics in managing patients with ART.
2. Measure free intracellular calcium levels in platelets from patients with ARF.
3. Look at the effect of loop diuretics on free calcium concentrations in platelets from patients
with ARF.
4. Examine the relationship between intraplatelet calcium concentration and APACF1E II score
in patients with ARF
5. Examine the relationship between resting energy expenditure and APACHE II score in
patients with ARF
In order to do this I enrolled 96 patients for the study described in chapter 5. Patients for the
studies described in chapters 6 and 7 were selected at random from the patients enrolled in the
loop diuretic study (chapter 5).
The work was carried out in the Renal and Intensive Care Units of the Royal Infirmary,
Glasgow while I held the post of research fellow.
Some of the work I am about to describe (chapter 5) was presented at the American Society of
Nephrology meeting in San Diego, November 1995 and has been published in Nephrology,
Dialysis, Transplantation.285 Chapter 6 has been prepared for publication.
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J Study 1 - Loop Diuretics in the Management of Acute
Renal Failure
5:1 Introduction
In clinical practice the temptation to use high doses of loop diuretics to increase urine flow
rate and thereby perhaps ameliorate the progress of ARF in patients with acute oliguria is
strong. The evidence for this practice is poor. Most reported studies have been largely
anecdotal, retrospective, non randomised or uncontrolled. 184-192
Theoretically, administration of loop diuretics should reduce the energy requirements of the
cells of the thick limb of the loop of Henle.286 These drugs act by inhibiting the Na+/2C1~
/K+ pump in the luminal cell membrane resulting in a fall in transcellular sodium transport.
Basal Na/K ATPase activity becomes unnecessary and the requirement of the cell for
oxygen falls. Brezis et al (1984) have shown that reducing active transport with frusemide
significantly reduces the damage to the thick ascending limb of Henle's loop in the isolated
perfused kidney.287 it is therefore possible that loop diuretics might 'protect' the cells of
the thick ascending limb during the hypoxia which accompanies hypotension and sepsis,
frequent predisposing factors in ARF, by reducing the need for energy consumption.
In 1983 a new loop diuretic, torasemide (Boehringer Mannheim) became available for
clinical trials. This prospective, double blind, randomised, placebo controlled study was
designed to compare the effect of frusemide, torasemide and placebo on the outcome of
patients with ARF in Glasgow Royal Infirmary. My aim was to answer the following
questions:
• Can loop diuretics convert oliguric ARF to non-oliguric ARF and is this associated with
an improvement in outcome ?
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• Can loop diuretics shorten the period of renal failure and reduce the need for dialysis?
• Can loop diuretics decrease mortality in ARF?
5:2 Subjects and methods
5:2:1 Patient selection
Patients aged 18 years and over referred to the Renal Unit of Glasgow Royal Infirmary with
potential ARF were seen by myself over a 3 year period. All had potentially reversible
acute intrinsic renal failure as defined by a rise in serum creatinine to over 180umol/l.
When first assessed each patient had bladder catheter drainage established and attempts
were made to correct all reversible pre-renal factors. A central venous catheter or
pulmonary artery catheter was inserted, arterial blood gases were measured and pulse
oximetry established. Obstructive uropathy was excluded by ultrasonography.
Those patients whose ARF did not respond to correction of pre-renal factors and who were
not obstructed were then considered for enrolment into the study. Exclusion criteria are
listed in Table 5:1. Written consent for the study was obtained either from the patient or, if
unconscious, from the next of kin, after explaining the various options and risks. The
protocol was approved the Ethics Committee of Glasgow Royal Infirmary. The
randomisation code was computer generated by software called Almedica Drug Labelling
System.
5:2:2 Methods
Patients were enrolled into the study at time (t) = 0, after a run in period of a minimum of
two hours. During this run in period two baseline hourly urine collections were made and
blood samples collected for subsequent biochemical tests (Table 5:2). An APACHE II
score was calculated for each patient during the run in period.281
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Serum biochemistry was repeated at t = 24 hours and thereafter on a daily basis at 0800
hours until Day 21 or, if sooner, death. In addition, serum osmolality was measured for the
first three days while mannitol was being used. This value was compared with that obtained
by calculating the serum osmolality using the formula:
(1.86 x serum sodium) + urea + glucose + 9.288
Urine was collected every six hours for the first 48 hours and thereafter every 24 hours.
Hourly urine flow rates were calculated. Urine biochemistry tests were carried out on each
sample (Table 5:2).
5:2:3 Treatment
All patients were given dopamine (continuous infusion of 2ug/kg estimated body
weight/min) and mannitol (infusion of 100ml of a 20% solution for 1 hour every 6 hours for
a maximum of 3 days), and were randomised to receive either frusemide, torasemide or
placebo as an intravenous infusion over 1 hour every 6 hours for up to 21 days. Previous
studies in chronic renal failure suggested that intravenous torasemide is equipotent to
frusemide.289,290 This study has made the assumption that this holds for ARF. The study
drug was given in a double blind fashion, initially in a dose of 3mg/kg estimated body
weight per dose. If the serum creatinine fell thereafter the dose of study drug was
decreased from 3mg/kg to 2mg/kg to lmg/kg and finally stopped as renal function
recovered. Both the study drug and dopamine were continued if the patient became dialysis
dependent or failed to recover renal function, for a maximum of 21 days, or until death
within 21 days. Although the study ended at day 21 the survivors continued on long term
follow up.
Mannitol was discontinued before day three if the patient remained severely oliguric or
anuric or became hyperosmolar ( measured osmolality - calculated osmolality > 17).
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5:2:4 Statistical analysis
A sample size of 90 was determined to be sufficient to detect a clinically significant
difference in outcome between the three groups (W Koehler, statistician, Boehringher
Mannheim - personal communication). The absolute values of the primary variables
(recovery, death or dialysis) were compared using chi-squared analysis. This was the most
appropriate test to use as I was predicting that patients given loop diuretic would have
different rates of recovery, death and dialysis, without specifying the direction of the
association. Other variables were analysed by means of analysis of variance (mean ± S.D.).
5:3 Results
A total of 278 oliguric patients were assessed for entry into the study (Figure 5:1), 25% of
whom recovered with adequate rehydration. A further 40% were excluded as they did not
fit the entry criteria or refused consent. The remaining patients (n= 96) were enrolled into
the study. Of these, 4 patients are excluded from the statistical analysis; 2 died in the run in
phase before the study drug was given and a further 2 patients were inappropriately enrolled
as they had been in another study within the preceding 30 days. 92 patients are therefore
available for analysis on an intention to treat basis. The sample size for each group is as
follows: torasemide n=30, frusemide n=32 and placebo n=30.
Table 5:3 shows demographic and clinical features. Patients in each of the groups were well
matched for age, sex, severity of illness and degree of renal impairment. The causes of
acute renal failure were similar in all three groups and have been amalgamated to show the
overall causes of ARF in Table 5:4.
A tabulated list of important screening data for each individual patient is shown in
Appendix 1. Appendix 2 is a list of outcome data for each individual patient.
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5:3:1 Loop diuretic (torasemide or frusemide) v placebo
Table 5:5 shows the outcome of treatment with loop diuretic or placebo. Patients given
torasemide or frusemide had a significant increase in urine output (Figure 5:2) and
fractional excretion of sodium (Figure 5:3) in the first 48 hours compared to placebo. These
patients did not receive any more mannitol than those in the placebo group. However, there
was no significant difference in the final outcome (recovery, dialysis or death) at day 21.
Twenty three percent of placebo patients recovered full renal function without requiring
haemodialysis compared to 17% and 28% for patients given torasemide and frusemide
respectively (p=0.56).
The proportion of patients requiring dialysis were not different in the three groups. The
time to dialysis in each group was torasemide 5.0 ± 5.0 days, frusemide 5.4 ± 5.7 days and
placebo 2.8 ± 1.2 days (p=0.35). Loop diuretic had no effect on the duration of dialysis
(torasemide 5.6 ± 4 days, frusemide 13.4 ± 13.7 days, placebo 13.2 ± 10.7 days, p=0.16).
The number of patients who died by day 21 without requiring dialysis was 47% and 41% in
the torasemide and frusemide groups respectively and 37% in the placebo group (p=0.73).
The total number of deaths by day 21 (dialysis and non dialysis dependent patients) was
70% in the torasemide group, 66% in the frusemide group and 50% in the placebo group
(p=0.24).
Table 5:6 shows the final outcome of all patients who required dialysis. There was no
significant difference between the groups. The day the serum creatinine started to fall
spontaneously was taken as an indication of renal recovery and there is no significant
difference between the groups (torasemide day 7 ± 7, frusemide day 5 ± 5, placebo day 8 ±
7, p=0.46).
Actuarial survival curves for the three groups are shown in Figure 5:4. This is continued up
to day 56, since all of the patients who died as a result of their primary illness had done so
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by then. At day 56 survival between placebo (43%), frusemide (38%), and torasemide
(30%) was not significantly different. Long term survival at 2 years was not significantly
different to survival at 56 days. Death after 56 days was due to causes not associated with
the primary illness such as trauma, ischaemic heart disease or cancer.
Daily median values for serum creatinine, sodium, potassium, calcium and C reactive
protein over the 21 day study period were calculated. There was no significant difference
in these between the three groups.
5:3:2 Oliguric v non-oliguric patients
The patients were divided into two groups - oliguric and non-oliguric - based on their urine
output during the first 24 hours after starting medication. Those patients whose urine
volume in the first 24 hours averaged >50ml/hour were termed non-oliguric. Conversely
those patients with hourly urine volumes <50ml/hour were termed oliguric. One patient has
been excluded from statistical analysis because he died prior to the first urine collection
after entry into the study. Therefore n = 91.
51 patients remained oliguric during the first 24 hours of the study while 40 were non
oliguric either spontaneously or because of diuretic treatment. By day fifty-six, 35 (69%) of
the oliguric patients had died compared to 17 (43%) of the non-oliguric patients (p=0.01).
The pre-study APACHE II score was better in the group who became non-oliguric (17.2 ±
5.9 v 20.6 ±5.5, p=0.008), as was the pre-study creatinine clearance (14 ± llml/min v 4 ±
4ml/min, p<0.0001).
In the group of patients who were non-oliguric, 8 (20%) were on placebo and 32 (80%) were
on a diuretic. In the non-oliguric placebo group (n=8) two patients (25%) had died by day
56. In the non-oliguric diuretic group (n=32), 15 (47%) had died by day 56 (p=0.3).
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5:4 Side effects
There was a non-significant increase in the incidence of seizures in the patients given loop
diuretic - torasemide 6, frusemide 6, placebo 1 (p=0.1). One patient on frusemide became
acutely deaf but recovered when the drug was stopped.
Torasemide caused a significant rise in y glutamyl transferase (y GT) an effect which is
reversible and given as a warning on the international data sheet.
Only 22% of patients continued on mannitol for 3 days. The reasons for stopping mannitol
are shown in Table 5:7. The patient who developed pulmonary oedema was not
hyperosmolar. Only one of the patients who became hyperosmolar had any symptoms
(confusion).
5:5 Discussion
Can loop diuretics convert oliguric ARF to non-oliguric ARF?
The use of high dose loop diuretics in patients with incipient ARF can significantly improve
urine output. Thus 57% of patients given torasemide and 48% of patients given frusemide
had a significant increase in urine volume in the first 24 hours compared to placebo (23%).
Patients who became non-oliguric had a lower mortality than those patients who remained
oliguric (43% v 69% p=0.01). However, patients who became non-oliguric were less ill as
evidenced by a significantly lower APACHE II score. They also may have had less severe
renal failure as their creatinine clearance was higher. However, this is an imprecise
measurement of renal function in these patients. On this evidence I cannot attribute a
'beneficial' effect on mortality solely to the use of loop diuretics.
Of more significance would have been a significant improvement in mortality between
those patients who became spontaneously non-oliguric with placebo and those whose
diuresis was induced by the use of loop diuretics. There was no difference in mortality at
5-7
day 56 between the non-oliguric group who had placebo (spontaneously non-oliguric) and
the non-oliguric group given loop diuretic. However, the number of patients in this
subgroup analysis is small and larger numbers of patients are required for statistical
analysis.
It has been suggested that continuous low dose infusions of frusemide might be preferable
to high dose bolus injections.291,292 ft js possible, therefore, that I might have achieved
an even greater diuretic effect by the continuous infusion of the loop diuretic. Few
controlled clinical trials comparing the diuretic and natriuretic response to infusion versus
bolus administration of loop diuretic have been published and most were published after this
study began. 188,291-293 They are flawed by the lack of data regarding severity of illness,
type of surgical procedure and post operative support required in the two groups of patients.
Thus, in view of the lack of definitive evidence in favour of continuous infusion of loop
diuretic at the time the study was started, 1 elected to use bolus therapy as this was standard
practice in Glasgow Royal Infirmary at that time.
In 1976 Kleinknecht et al studied 55 patients with established oliguric ARF.185 Thirty
three were given a variable dose of frusemide while 33 were given only intravenous fluids.
There was no significant reduction in the duration of oliguria in the group given loop
diuretic. Minuth and colleagues found a sustained diuresis in 22% of 104 patients given a
variable does (40 - 500 mg) of frusemide. 184 Other groups however, have shown that
intravenous frusemide modifies ARF by causing sustained polyuria. 186-192
Can loop diuretics shorten the period ofrenal dysfunction and reduce the needfor dialysis?
Renal recovery was considered to begin when the serum creatinine started to fall
spontaneously, without dialysis. There was no significant difference in the time to renal
recovery between the three groups. The need for dialysis was also not different. These
findings agree with the studies ofBrown and Borirakchanyavat.190,192
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Minuth and colleagues, however, found a reduction in the need for dialysis in patients given
loop diuretic. 184 Cantarovich showed that a progressive does of frusemide (100 -
3200mg/day in geometric progression on continuous days) shortened the period of renal
dysfunction, presumably because of the high average daily dose of frusemide (1.24g/day)
received by the progressive dose group compared to the fixed dose group (600mg/day).186
I gave a maximum dose of loop diuretic 1,2g/day.
Can loop diuretics decrease mortality in ARF?.
This prospective randomised double blind study failed to demonstrate an improved
mortality in patients treated with loop diuretics, a finding in keeping with most previous less
well controlled studies. 185,188,190 Only Anderson et al showed a reduction in
mortality in the subgroup of patients given frusemide and who were non-oliguric.191 This
subgroup also had a lower fractional excretion of sodium and lower urinary sodium than
those who did not respond to the diuretic, implying they had less severe renal failure as
renal tubular sodium reabsorption continued. This is in keeping with my observation that
the patients who became non-oliguric after loop diuretics had significantly less severe organ
failure and better renal function at presentation.
It could be argued that the use of mannitol and dopamine in all the patients may have
affected the results. At the time ethical approval for the study was sought the use of these
two drugs was 'routine', despite the lack of evidence in their favour. Recently there has
been evidence suggesting that both mannitol and dopamine may not be beneficial in ARF
and indeed may even be harmful.
In healthy volunteers, dopamine causes a selective increase in renal blood flow resulting in a
natriuresis and diuresis. 193 However, Breslow et al have shown that in pigs with endotoxic
shock renal vascular autoregulation and vasodilatation may already be maximal and
therefore unable to be manipulated further by pharmacological methods.294 Baldwin et al
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studied 37 patients having elective repair of an abdominal aortic aneurysm or
aortobifemoral grafiting.295 None of the patients had renal failure, but in this prophylactic
study low dose dopamine (n=18) did not show any advantage over adequate peri-operative
hydration (n=19). Duke et al showed that low dose dopamine given to critically ill patients
with a normal serum creatinine caused a diuresis but did not improve creatinine
clearance.296
In a porcine model of haemorrhagic shock Segal et al (1992) showed that animals given
low-dose dopamine (2ug/kg/min) had an earlier onset of gut ischaemia associated with a
decreased ability to extract oxygen than shocked animals not given low dose dopamine.297
They suggested that low dose dopamine used to treat shocked, oliguric patients may have a
detrimental effect on oxygen transport and utilisation in the gut which potentially could
cause occult gut ischaemia, translocation of bacterial products and development of multi-
organ failure. Scanned et al (1994) have shown that gastric submucosal PO2 does correlate
with gut translocation.298
Chertow et al assessed dopamine administration in 497 patients with early progressive renal
failure.299 Dopamine was given 'at the discretion of the attending physician'. 69% of
oliguric and 68% of non oliguric patients were therefore given dopamine. The overall
mortality at 21 days was 31% with and 21% without dopamine and the tendency to
increased mortality in the dopamine group was more obvious in those patients who were
oliguric (49% with v 26% without dopamine). Dialysis requirement at day 14 was said to
be significantly higher in the dopamine group (47%) compared to the group not given
dopamine (36%). Unfortunately no indicators of statistical significance are included in the
abstract. Nor is there any mention of severity of illness or renal function in the two groups.
It is possible that patients given dopamine were in fact more ill with more severely impaired
renal function than the group not given dopamine. The waters are further muddied by the
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fact that the study was originally designed to compare the effect of ANP with placebo. The
authors do comment that regardless of the original treatment assignment (ANP or placebo)
dialysis was still more common in patients given dopamine, although no mention of the
effect of the primary treatment assignment and dopamine on mortality is made.
Heymann et al have shown that a mannitol infusion decreased rat outer medullary O2
tension from 22±4 to 14±3mmHg (p<0.002) without changing the cortical oxygen
tension.300 Thus mannitol has the potential to perpetuate the medullary hypoxia seen in
ARF. It may do this by increasing the oxygen requirements of the already hypoxic mTAL.
By washing out intratubular casts mannitol causes an increase in inulin clearance; it also
causes decreased fluid absorption in the proximal tubule and therefore may cause increased
delivery of filtered solutes to mTALs in nephrons not blocked by intratubular casts. Both
these effects will increase the metabolic demand of the mTAL, but there will be no increase
in blood flow to meet the increased metabolic demand as capillaries in the outer medulla are
blocked by trapped red blood cells. The result is more hypoxia and further injury.
The prophylactic use of mannitol has been reported to prevent RBC trapping in the rabbit
kidney. 115 This may be related to its action as a free radical scavenger as other free radical
scavengers have also been shown to prevent RBC trapping.H5 However, Hellberg et al
showed that administration of mannitol in a dose dependent manner after the ischaemic
event was associated with an increase in RBC trapping in the inner stripe of the outer
medulla.301
Thus the available experimental evidence and the lack of controlled studies suggest that at
present mannitol and low-dose dopamine do not have a role to play in the management of
ARF. Were the study to be redesigned neither of these two drugs would be included in the
protocol. However, as patients in all three treatment groups received mannitol and
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dopamine, any differences noted between the groups as a result of treatment would have
been due to loop diuretic.
5:6 Conclusion
This prospective, placebo- controlled, double - blind randomised study has shown that loop
diuretics have no beneficial effect on the duration of renal dysfunction, the need for dialysis
or on mortality in ARF. Patients who become non-oliguric (with or without a loop diuretic)
have a better survival but are less ill and have less severe renal failure than patients who
remain oliguric.
80% of patients who became non-oliguric were on a loop diuretic, but the difference in
mortality between this group and the group receiving placebo who became non-oliguric is
not significant. However, the numbers in this subgroup analysis are too small for any firm
conclusions to be drawn.
A trial specifically addressing the question of mortality in patients who become non-oliguric
either on loop diuretic or placebo would need to enrol 518 patients in each group. This
assumes reducing overall mortality from ARF to 40% or less is a significant improvement, a
level of statistical significance of 0.05 and a power of 0.9. In my study 44% of patients
enrolled became non-oliguric as a result of intervention (placebo or loop diuretic).
Therefore a total of 2354 patients would need to be enrolled and given loop diuretic or
placebo in order to have the required number of patients in the spontaneously and
pharmacologically induced non-oliguric groups. This in turn means that in the order of
6730 patients with ARF would need to be assessed for suitability for entry into such a study.
It may therefore never be performed.
In very ill patients many insults contribute to the onset of ARF; most patients suffer from
multiple-organ failure. Perhaps it is a naive to suppose that a drug acting primarily on the
kidneys would have a beneficial effect on a multisystem disorder and so improve survival.
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My studies have shown that loop diuretics have little effect on the natural history of ARF.
The conversion of oliguric into non-oliguric ARF however, could be an indication for their
use in order to improve fluid balance, despite their lack of evidence on outcome. If we are
to significantly improve mortality in these patients attention should be focused on the early
detection and management of all aspects ofmulti organ failure.
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Figure 5:1 Patients assessed for entry into the study
278 patients
70 patients dehydrated
108 patients on loop or osmotic diuretics
2 patients refused consent
2 patients in another study
96 patients enrolled
Inappropriately enrolled
Died in run in phase
92 patients available for analysis
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Figure 5:2 Urine output in the first 48 hours (median values)
Vol. (l/24hrs)
Day 1 Day 2
©Torasemide O Frusemide ©Placebo
Urine output (1/24 hours)
Screen 6hr 12hr
median mean SD median mean SD median mean SD
Tor 0.60 0.63 0.46 1.41 2.69 2.64 1.41 3.18 3.00
Fru 0.40 0.71 0.97 0.99 2.97 4.57 1.24 3.47 4.74
Pla 0.41 0.47 0.38 0.58 0.78 0.70 0.70 0.89 1.10
18hr 24hr Day2 6hr
median mean SD median mean SD median mean SD
Tor 1.64 3.2 3.15 1.41 3.23 3.32 1.86 2.82 2.82
Fru 1.50 3.35 4.03 1.80 3.07 4.05 2.28 2.89 3.80
Pla 0.75 1.11 1.28 0.79 1.4 1.79 0.70 1.29 1.51
12hr 18hr 48hr
median mean SD median mean SD median mean SD
Tor 2.06 2.97 3.03 1.60 3.64 3.51 1.90 3.3 3.37
Fru 1.57 2.96 4.08 1.30 2.44 3.30 1.27 2.58 3.31
Pla 0.66 1.22 1.43 0.62 1.21 1.50 0.76 1.08 1.18
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Figure 5:3 Fractional excretion of sodium in the first 48 hours (median values)
%
Day 1 Day 2
o Torasemide O Frusemide ® Placebo
Fractional excretion of sodium (%)
Screen 6hr 12hr
median mean SD median mean SD median mean SD
Tor 1.7 7.8 25.3 11.0 11.6 7.9 15.9 19.8 20.3
Fru 1.7 3.7 5.6 11.3 15.0 12.7 20.2 21.4 16.2
Pla 1.4 5.8 9.3 1.9 4.0 7.0 3.2 4.8 5.8
18hr 24hr Day2 6hr
median mean SD median mean SD median mean SD
Tor 18.7 27.5 28.2 18.0 27.5 37.6 17.7 23.3 25.0
Fru 18.2 22.7 15.7 18.3 22.9 16.3 20.9 21.8 15.2
Pla 3.1 5.3 5.7 4.2 6.2 6.9 5.1 7.2 7.4
12hr 18hr 48hr
median mean SD median mean SD median mean SD
Tor 17.3 21.0 17.3 19.3 19.1 13.0 12.9 17.2 12.5
Fru 19.7 18.5 11.0 22.5 23.2 14.0 22.3 23.4 11.7
Pla 4.7 6.8 7.6 4.4 7.2 7.8 2.6 5.9 6.4
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Figure 5:4 Actuarial survival for the three groups of study patients up to day 56
Days
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Table 5:1 Exclusion criteria
Exclusion criteria
Patients with either pre or post renal failure.
Patients given a loop or osmotic diuretic within the preceding 12 hours.
Patients given frusemide >100mg (or equivalent loop diuretic) in the preceding 48 hours.
Administration of any investigational substance within 30 days preceding the first dose
of the study drug.
Women using inadequate contraception.
Women who were pregnant or lactating.
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Table 5:2 Serum and urine measurements
Urine Serum








Table 5:3 Demographic and clinical features
Torasemide Frusemide Placebo P
Age (years) 58.7+13.8 59.2 ± 16.5 58.3 ± 14.1 0.97+
Sex (%)
Male 53 50 63
Female 47 50 37 0.55*
Apache II score 19.6 ±4.5 19.1 ±7.2 18.4 ±5.8 0.77+
(Pre-study)
Creatinine clearance (ml/min) 10 ± 11 8 ± 9 7 ± 8 0.45+
Hourly urine volume (ml/hr) 24 ± 18 32 ±45 20 ± 16 0.32+
*
chi-square test
+ analysis of variance
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Table 5:4 Cause of acute renal failure
Cause of acute renal failure Number
Septic shock / sepsis 31
Infection 13
Abdominal aortic aneurysm surgery 14
Acute liver failure 5





Table 5:5 Outcome of acute renal failure at day 21
Torasemide (%) Frusemide (%) Placebo (%) P
Increase in urine flow 57 48 23 0.02*
Renal recovery 17 28 23 0.56*
Dialysis required 36 31 40 0.87*
Time to dialysis (days) 5.0 ±5.0 5.4 ±5.7 2.8 ± 1.2 0.35+
Duration of dialysis
(days)
5.6 ±4 13.4 ± 13.7 13.2 ± 10.7 0.16+
Death by 21 days 47 41 37 0.73*
Alive day 56 30 38 43 0.70*
* chi-square test
+ analysis of variance
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Table 5:6 Final outcome of patients requiring dialysis
Torasemide Frusemide Placebo (%)
(%) (%)
Dead 64 60 42
Alive 36 40 58
chi-square test, placebo versus frusemide or torasemide, p=0.52
Table 5:7 Reason for stopping mannitol
Reason for stopping mannitol Number
Severe oliguria / anuria 27
Death before day 3 24
Hyperosmolality 15
Acute pulmonary oedema 1
Renal recovery 2
Withdrawn from study 2
6 Study 2 - Intraplatelet Calcium Levels in Healthy
Volunteers and Patients with Acute Renal Failure
and Multi-Organ Failure
6:1 Introduction
Elevated free cytosolic calcium([Ca]f), found in cells injured by ischaemia has been proposed
as one of the mechanisms important in the pathogenesis of ischaemic cell injury.302-304
Schanne et al studied the viability of hepatocytes exposed to membrane active toxins. In the
presence of extracellular calcium all hepatocytes were killed in 1-6 hours but remained viable in
the absence of extracellular calcium.303 Snowdowne demonstrated a rise in intracellular
calcium levels in cultured monkey kidney cells after 1 hour of anoxia and substrate removal.282
High [Ca]f causes an uncoupling of mitochondrial oxidative phosphorylation resulting in
reduced ATP stores.04 Wilson et al showed that accumulation of intra-mitochondrial calcium
occurs following reperfusion of ischaemic renal tissue, and that there is a highly significant
correlation between raised mitochondrial calcium concentration and decreased mitochondrial
respiration.95 High [Ca]f also causes activation of phospholipases resulting in an alteration in
membrane permeability and membrane enzyme activity.98,305,306 Activation of intracellular
proteases in ARF in the presence of raised [Ca]f will convert xanthine dehydrogenase to
xanthine oxidase which in turn leads to the production of hydroxyl radicals and tissue
injury. 104 jn addition calcium has been shown to potentiate the oxygen free radical mediated
injury to mitochondria. 112
Two clinical studies have shown that sepsis increases erythrocyte free cytosolic calcium and
lymphocyte free cytosolic calcium.283,284
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Loop diuretics have been shown to cause a significant decrease in [Ca]f in platelets from
patients with essential hypertension and in red blood cells from normal volunteers.307,308 The
authors do not speculate on the possible mechanism for this effect. In an experimental model of
ischaemic ARF loop diuretics prevented the rise in mitochondrial calcium normally seen in
oliguric ARF.309 jf iGOp diuretics could be shown to reduce cytosolic calcium in the cells of
patients with ARF then the use of loop diuretics should theoretically attenuate renal tubule cell
injury and perhaps improve the clinical outcome.
Studying renal tubule cells in a clinical setting is not possible and a suitable alternative is
needed. White blood cells, red blood cells and platelets are easily accessible. I elected not to
use white blood cells as the cell population is not homogenous. Haemoglobin in red blood cells
interferes with the fluorescence of quin2, the fluorescent probe used to measure intracellular
calcium levels in my studies. Although non of the three cell lines considered bear any
resemblance to tubule epithelial cells, platelets do have some features in common with vascular
smooth muscle cells, namely a calcium dependent contraction-coupling mechanism and a.2-
adrenoceptor operated calcium channels.310>311 As with vascular smooth muscle angiotensin
II and vasopressin may also promote calcium influx.312 Thus platelets are a good model to
study in clinical ARF to assess the possible role of intracellular calcium in the initiation
(vascular) phase of ARF. It is possible that similar changes may occur in tubule epithelial cells,
contributing to cell death and the maintenance ofARF.
I therefore measured free intracellular calcium levels in platelets ([Ca]j) in patients with ARF,
patients with multi-organ failure (MOF) but normal renal function, and in normal subjects.
Patients with ARF and normal subjects also had [Ca]j levels measured after administration of
loop diuretic or placebo.
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6:2 Subjects and methods
6:2:1 Normal volunteers
16 healthy adult volunteers were entered into the study (10 males and 6 females). All subjects
had normal renal function, no history of acute or chronic illness and were not taking any
medication. The mean age of controls was 30 years (range 25 - 40). Informed written consent
was obtained.
On the first study day (control) at 1300 hours a 16G indwelling plastic cannula was inserted into
the forearm, the tourniquet removed, and 45 ml blood taken into sodium citrate for
measurement of [Ca]j in platelets. The following day (day 2) at 1000 hours an intravenous
injection of either frusemide 20mg/2ml, torasemide 10mg/2ml or placebo 2ml was given. The
study was double blind and neither the investigator nor the subject were aware of what was
being given. Three hours later a further 45 ml blood was taken into sodium citrate as before for
measurement of [Ca] j. During the second study day patients were encouraged to drink freely to
prevent dehydration. Estimation of [Ca]j took place immediately after venepuncture.
A one week wash out period was allowed and days 1 and 2 repeated one week and two weeks
later. Each subject therefore received each of the loop diuretics and placebo in a random order.
6:2:2 Acute renal failure patients
Seven patients with ARF participated in this study - 2 females and 5 males; mean age 60 years
(range 46 - 69). They were patients who were in the study described in chapter 5. 45ml of
blood was taken for intraplatelet calcium estimation as for the normal volunteers and patients
were started on frusemide, torasemide or placebo 3mg/kg over 1 hour every 6 hours, a
continuous IV infusion of low dose dopamine and 20g mannitol IV over 1 hour every six hours.
Five of the patients received loop diuretic. 24 hours later a further 45ml of blood was taken for
estimation of intraplatelet calcium.
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6:2:3 Multi-organ failure patients
Five patients with multi-organ failure but normal renal function were entered into this part of
the study. The mean age was 50 years (range 32 - 64). A single sample of 45ml of blood was
taken for intraplatelet calcium estimation as above.
MOF patients were not given diuretic.
6:3 Laboratory methods
6:3:1 Measurement of intraplatelet calcium
[Ca]j was measured using a fluorescent probe - quin2 acetoxymethylester.313 Platelet rich
plasma (PRP) was prepared by collecting whole blood into 3.9% sodium citrate (9ml whole
blood/1 ml sodium citrate), and centrifuging at 250 g for 5 min at room temperature. PRP was
incubated at 37°C for 30 min with quin2 (2ul quin2 were added to each ml PRP).
Ethyleneglycolbis(aminoethylether)tetra-acetate (EGTA; 5mmol/l; Fluka) was added to bind to
any extracellular calcium, and PRP then centrifuged at 250 g for 10 min at room temperature.
The supernatant was removed and the pellet resuspended in platelet buffer titrated to pH 7.3 at
37°C (recipe for platelet buffer shown in Table 6:1). The buffer was calcium free to prevent
platelet aggregation during centrifugation. The cells in the suspension were counted in a
THCoulter Counter (Technicon H-l system). The concentration of cells was adjusted to 1.5-2 x
108/ml and the suspension was dispensed into 9 cuvettes and placed in a water bath at 37°C.
The first cuvette was placed into the spectrofluorometer and the background fluorescence was
measured with a Perkin-Elmer LS-3B spectrofluorometer at 339nm excitation and 492nm
emission.
20ul of 0.1M CaCl2 was then added to the cuvette (Figure 6:1:a). In health there should be no
change in the fluorescence signal since the added calcium should not leak across the plasma
membrane into the platelets (Figure 6:2).
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The cells were disrupted with 20ul of digitonin thereby releasing the intracellular quin2 which
then binds to the added calcium giving rise to the maximum fluorescence signal, Fmax (Figure
6:l:b). The quin2 is then fully saturated. 20ul of MnCl2 was added; manganese displaces
calcium from the quin2 and therefore gives rise to a very low signal, Fm[n (Figure 6:1 :c).
The intraplatelet calcium concentration can then be calculated using the equation:
[Ca]i=115(F-F/w/„./Fwax.-F)314
where 115 is the equilibrium dissociation constant in nmol/1, F the fluorescence of the intact cell
suspension, Fmax. the maximum fluorescence after the cells have been disrupted with digitonin
(20ul) and Fmjn the minimum fluorescence obtained after addition of 20ul 2mmol/l MnCl2-
The procedure was repeated for cuvettes 2 and 3.
6:3:2 Effect of arginine vasopressin
Arginine vasopressin (AVP) stimulates influx of calcium from the suspension into the platelet
(mechanism 1, Figure 6:3), as well as a release of intracellular stores of calcium into the cytosol
(mechanism 2, Figure 6:3). As quin2 is only found inside the platelet, the fluorescence signal
obtained after addition ofAVP gives an indication of total intracellular calcium (Figure 6:3).
In cuvettes 4, 5 and 6 the response of platelet [Ca]j to AVP (lumol/1) was measured in the
presence of lmmol/1 calcium (20ul of 0.1M CaCl2 added to the suspension). The maximum
fluorescence obtained was therefore due to influx of calcium from the suspension and release of
intracellular stores.
6:3:3 Effect of AVP and EGTA
The extracellular calcium concentration was then reduced to negligible concentrations in
cuvettes 7, 8 and 9 by adding 50ul of 200mM EGTA. In the presence of EGTA, there is no
calcium influx from the suspension into the cell and the fluorescence signal obtained when AVP
is added comes solely from release of intracellular stores into the cytosol (Figure 6:4).
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6:4 Statistical analysis
Statistical analysis of intracellular calcium levels was performed using the Mann-Whitney U-
tests. Results are expressed as the median and 95% confidence interval for the absolute
difference between A minus B. Apache II scores were compared using students' t-test.
Measures of relationship were calculated by Pearson's correlation test. P values <0.05 were
taken to indicate statistical significance.
6:5 Results
6:5:1 Normal volunteers
Tables 6:2, 6:3 and 6:4 show the [Ca]j (measured as the level of fluorescence) obtained at the
start of the experiment (Table 6:2) and after the addition of AVP (Table 6:3) and then
AVP/EGTA (Table 6:4), pre and post loop diuretic or placebo. There was no significant
difference in the basal [Ca]j before or after loop diuretic or placebo (Table 6:2). The presence
of a negative value in the confidence interval means that although Basal A is greater than Basal
B, it is possible within the 95% confidence interval range that the absolute value of Basal B may
be greater than Basal A.
The addition of AVP in the presence of lmmol/1 extracellular calcium caused a rise in the
fluorescence signal as expected (Table 6:3). In the absence of extracellular calcium the rise in
fluorescence was much less - the signal coming solely from the intraplatelet stores of calcium
(Table 6:4).
There was no significant difference in the rise in [Ca]j after either AVP or AVP/EGTA in
normal subjects before or after loop diuretic.
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6:5:2 ARF patients
The baseline results before administration of loop diuretic are shown in Table 6:5.
Basal levels of [Ca]j were significantly higher in ARF subjects than normal volunteers (109nm
v 92.4nm, p=0.04). The rise in [Ca]j after the addition of AVP tended to be higher in control
subjects although it did not reach significance (584.8nm v 346nm, p=0.4); after the addition of
AVP/EGTA there was a smaller rise in the fluorescence signal obtained from the ARF group
compared to controls which was not statistically significant (116nm v 165.8nm, p=0.14).
Post diuretic there were no significant changes in basal levels of [Ca]j nor in the response to
AVP (Table 6:6).
The higher basal levels of [Ca]i in the ARF patients were compared with the APACHE II scores
but there was no correlation between the two.
6:5:3 MOF patients
To see whether the changes in the ARF patients were due to ARF or the presence of severe
illness a group of patients with multi-organ failure but normal renal function were compared
with the normal volunteers (Table 6:7). The APACHE 11 score in the MOF patients was
similar to the APACHE 11 score in the ARF patients (13.8 ± 6.9 v 17.7 ± 6.2 respectively,
p=0.36) indicating that the groups were comparable in terms of severity of illness. Basal [Ca]j
was higher in the MOF group than the normal volunteers, but not significantly so (105.9nm v
92.4nm, p=0.1). As for the ARF group the rise after AVP was less than that in normal
volunteers, significantly so this time (298.7nm v 584.8nm, p=0.04). The smaller rise after
AVP/EGTA compared to normal volunteers was not significant (128.8nm v 165.8nm, p=0.2),
(Table 6:7).
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6:5:4 Summary of findings
1. Basal [Ca]j was significantly higher in ARF patients than in normal volunteers.
2. Basal [Ca]j tended to be higher in patients with MOF than in normal volunteers, but the
difference was not statistically significant.
3. After AVP the rise in [Ca]j was higher in normal volunteers compared to ARF patients, but
not significantly so.
4. After AVP the rise in [Ca]j was significantly higher in normal volunteers compared to MOF
patients.
5. After the addition of AVP/EGTA there was a smaller rise in [Ca]j in ARF patients
compared to the normal volunteers that did not reach statistical significance.
6. Diuretics had no effect on the basal level of [Ca]j nor the response to AVP.
7. There is no correlation between [Ca]j and the APACHE II score in ARF.
6:6 Discussion
Normal volunteers
Platelets from normal volunteers behaved as expected with a rise in [Ca]j after AVP due to an
influx of calcium across the plasma membrane and release of intracellular stores of calcium into
the cytosol. The calcium then bound to free quin2 in the cytosol and caused a rise in the
fluorescence signal. In the presence of EGTA, and therefore in the absence of extracellular
calcium, the increase in the fluorescence signal was less, coming solely from released
intraplatelet stores of calcium. The magnitude of the difference suggests that in the presence of
AVP and extracellular calcium, most of the rise in intracellular calcium comes from the influx
of calcium across the plasma membrane rather than from the intracellular stores.
Volunteers in the control group were significantly younger than patients in the two study
populations. However, basal levels of [Ca]j in normal volunteers in this study are not different
from those found in normal subjects in a previous study looking at platelet cytosolic free
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calcium in essential hypertension where the age range of subject was 15-71 years.307 Age
itself probably has no effect on intraplatelet levels of calcium, although hypertension does.
None ofmy normal volunteers had hypertension. One patient in the ARF group and none of the
patients in the MOF group were hypertensive.
ARF and MOF patients
Basal levels of [Ca]i in the ARF patients were significantly higher than in controls. It is
possible that the small sample size could give rise to a Type I error. Although basal [Ca]i levels
were also higher in the MOF group this was not statistically significant. The rise after AVP
tended to be less in ARF and MOF compared to controls - perhaps because a greater percentage
of the quin2 in the cytosol was already bound to calcium. The smaller rise in [Ca]j after
EGTA/AVP would imply that the stores of calcium were depleted. It is unlikely that there was
not enough quin2 to bind to the calcium released from the stores after AVP/EGTA. This is
because in the presence of extracellular calcium and AVP without EGTA, there was enough
quin2 to bind to calcium released from stores and calcium from the extracellular fluid.
Depletion of intracellular stores of calcium may reflect alteration of membrane phospholipids in
very sick patients. The platelet cell membrane was clearly abnormally permeable to calcium as
the fluorescence signal rose after the addition of extracellular calcium (Figure 6:5) implying
transfer of calcium across the plasma membrane from the extracellular fluid to the cytosol.
Compare this with the unchanged signal obtained from platelets from a normal volunteer
(Figure 6:2). It is known that ischaemia alters the composition of plasma membrane
phosopholipid.98,305 Presumably in these sick patients, despite optimisation of oxygen
delivery, oxygen uptake and utilisation is impaired and cellular hypoxia results leading to
alteration of membrane phospholipids. This would allow efflux of intracellular stores of
calcium into the cytosol as well as influx of extracellular calcium. A reduction in Ca ATPase
activity due to reduced ATP levels would reduce calcium efflux from the cell.91
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Gram negative sepsis often results in MOF with ARF. Lipid A from the gram negative bacterial
cell wall is believed to be responsible for the cytotoxicity.^ 15 Mayeux and Shah showed that
the cytotoxicity of lipid A in the renal tubular epithelial cell line LLC-PK4 was mediated by a
rise in intracellular calcium that preceded cell death and that buffering of intracellular calcium
with quin2 was protective.316 Interestingly they showed that extracellular calcium was not
necessary for the rise in [Ca]j and that TMB-8 which inhibits release of intracellular stores of
calcium protected the LLC-PR] cells from lipid A cytotoxicity. Their results suggest that in
endotoxaemia the release of intracellular calcium is important for the cytotoxic effect of lipid A.
Todd and co-workers demonstrated a significant rise in erythrocyte free cytosolic calcium
following endotoxin (84.523nm ± 5.019 v 40.45Inn ± 2.923, p<0.001), and a similar rise
occurred in septic patients (septic 96.261nm ± 7.511 v non-septic 45.376nm ± 2.925,
p<0.001).284 However, others did not find an increase in lymphocyte free intracellular calcium
levels following endotoxin and tumour necrosis factor (TNF), although lymphocyte free
intracellular calcium levels were significantly higher (p<0.05) in septic patients (176nm ± 12)
compared to non-septic head injured (llOnm ± 11), cardiac surgical (112nm ± 9) or healthy
controls (112nm + 5).283 This group did show that lysophosphatidylcholine (an endogenous
membrane lipid released during ischaemia) did significantly increase lymphocyte free
intracellular calcium in a dose dependent manner.
Intramitochondrial calcium levels have been shown to be raised after renal ischaemia.97,317
The rise in calcium may have been secondary to reduced ATP dependent efflux of calcium and
also increased permeability of the cell membrane to calcium.
In a clinical setting renal tubule cells cannot be studied directly and a suitable, easily accessible,
alternative model is needed. I therefore elected to study the effect that ARF has on the
concentration of intraplatelet calcium. As the renal medulla is susceptible to hypoxia^ it is
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unlikely that platelets would be hypoxic without the tubules also being affected, although the
reverse is not necessarily true.
Levels of intracellular calcium in patients with ARF have not been measured before, although
sepsis is associated with increased free erythrocyte calcium and lymphocyte free cytosolic
calcium.283,284 Presumably the effect of sepsis on intracellular calcium is also due to hypoxia.
It is possible that many cells, including renal tubule cells, are similarly affected by hypoxia.
Studies on isolated tubule suspensions show an early rise in permeability to calcium after
anoxia.317
I have shown that in ARF the basal levels of [Caj] are significantly higher than in normal
volunteers and that in MOF the basal [Caj] levels tend to be higher although the difference is
not statistically significant. I have also shown that the intracellular stores of calcium are
significantly reduced in MOF and tend to be low in ARF. The fluorescence signal obtained
after addition of calcium would suggest that the permeability of the platelet membrane is
abnormal and appears to allow leakage of added extracellular calcium into the cytosol. During
the post ischaemic reflow period calcium could leak back through the abnormal membrane into
the cytosol. In addition, abnormally permeable internal membranes would allow leakage of
stored calcium into the cytosol.
I hypothesised that this rise in intracellular calcium might be related to the severity of illness
and thus correlate with the APACHE II score, an objective scoring system used to stratify
patients according to prognosis. However, I could not show any correlation between the
APACHE II score and the intraplatelet calcium level in patients with ARF.
Loop diuretics had no effect on intraplatelet calcium levels in platelets from patients with ARF.
It is possible that the alteration in membrane structure due to phospholipase activity affects the
binding sites of drugs resulting in reduced drug action. Another possibility is that any lowering
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effect of loop diuretics on [Ca]j may be overwhelmed by the leakage of calcium into the cytosol
from the extracellular fluid and internal calcium stores resulting in a net rise in [Ca]j.
The loop diuretics were not given until after the hypoxic or nephrotoxic insult. Had they been
given prior to the renal insult one could speculate that the results may have been quite different.
However, in a clinical setting this is usually not possible.
6:7 Conclusion
In summary, abnormally permeable cell membranes may allow an influx of calcium during the
post ischaemic reflow period in ARF. Mitochondria buffer the calcium at the expense of
oxidative phosphorylation and ATP production, thus reducing the efficiency of the Ca ATPase
extrusion mechanism. I have shown that [Ca]{ is high in platelets from patients with ARF,
possibly due to an influx of calcium from the extracellular space across the damaged cell
membrane, and also release of intracellular stores of calcium. The administration of loop
diuretics have been shown to prevent the rise in mitochondrial calcium concentration in animal
models ofARF.309 j could not detect this response to loop diuretics in patients with ARF.
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b. Cell disrupted with digitonin. Quin2 binds to Ca resulting in Fmax.
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Figure 6:1 (continued) Quin2 / calcium interaction
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C. After addition ofmanganese. Calcium is displaced from quin2 resulting in F min.
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Figure 6:2 Fluorescence signal from platelets from a healthy volunteer
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Intracellular stores of calcium
F max due to calcium influx from the suspension, mechanism (1) and release of
intracellular stores, mechanism (2)
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Intracellular stores of calcium
EGTA binds to calcium in the suspension. Intracellular stores of calcium released after
addition ofAVP, mechanism (2)
F max due to release of intracellular stores
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Figure 6:5 Fluorescence signal from platelets from a patient with ARF
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Titrated to pH 7.3 with KOH 1M
Table 6:2 Basal levels of [Ca] j (control group)
Basal A Basal B 95% confidence interval p
Placebo 844 718 -11.4,21.6 0X~
Torasemide 103.3 82.4 -1.3,33.6 0.07
Frusemide 84.4 92 -24.1, 15.6 0.6
A - pre diuretic / placebo
B - post diuretic / placebo
All units are nm.
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Table 6:3 Response to AVP (control group)





A - pre diuretic / placebo
B - post diuretic / placebo
428.5 625.7 -450.5,118.1 0.5
666.8 520.0 -38.9,69.3 0.5
613.2 630.0 -337.2.230.8 0.7
All units are nm.
Table 6:4 Response to AVP/EGTA (control group)
EGTA A EGTA B 95% confidence interval p
Placebo 172.0 1744 -47.4,41.1 LO
Torasemide 176.0 172.0 -57.3,38.4 0.9
Frusemide 160.8 176.8 -57.8, 32.9 0.1_
A - pre diuretic / placebo
B - post diuretic / placebo
All units are nm.
6-22
Table 6:5 ARF patients v controls (before loop diuretic)
ARF Control 95% confidence interval p
Basal liO 92A -62.8, 1.0 004
AVP 346.0 584.8 -358,510 0.4
EGTA 116.0 165.8 -34.9,111.3 0.1
All units are nm.
Table 6:6 ARF patients - pre and post diuretic
A B 95% confidence interval P
Basal 109.0 166.0 -167.0, 47.0 0.4
AVP 346.0 289.0 -157.9, 747.0 0.8
A - pre diuretic
B - post diuretic
All units are nm.
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Table 6:7 MOF patients
MOF Control 95% confidence p
interval
Basal 105.7 92A -55.5,6.2 oT
AVP 298.7 584.8 9.4,639.4 0.04
EGTA 128.8 165.8 -155.2,89.0 0.2
All units are nm.
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7 Study 3 - Resting Energy Expenditure and the
APACHE II Score in Patients with Acute Renal
Failure
7:1 Introduction
7:1:1 APACHE II score
The APACHE II score is an objective scoring system used to stratify patients according to
prognosis.248 yiie score is compiled from various physiological measurements including
vital signs, laboratory investigations, Glasgow Coma Scale score and in addition points are
given for significant chronic health problems and age. The higher the final score the greater
the risk of hospital death.
By providing a measure of disease severity it is useful in clinical trials to determine whether
control and treatment groups are similar. It also acts as a marker of physiological stress.
7:1:2 Resting energy expenditure and the respiratory quotient
REE is the energy expended by an awake, alert subject at rest in the post absorptive
state.249 fhis value has been shown to be approximately 10% higher than the true basal
energy expenditure (BEE) as measured in deep sleep.248,249 Several factors - BSA, sex,
age, diet, sleep, breathing, exercise and disease have been shown to influence the
REE.248,249,251,253-255
Resting energy expenditure accounts for 75-90% of total energy expenditure; diet induced
thermogenesis, shivering and non-shivering thermogenesis and exercise make up the
rest.244,251
Resting energy expenditure (REE) may be measured at any time of the day as long as the
measurement conditions outlined in the methods section are adhered to.
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The Harris-Benedict equation was reported to predict BEE, but the conditions of the original
test imply that the results are more akin to the REE.259,294-296 Therefore, REE can be
predicted using the Harris-Benedict equation (HBREE).259 jhe ratio of REE measured
using indirect calorimetry to the predicted REE (REE/HBREE) can be used to determine
whether patients are hypermetabolic (ratio >110%), normometabolic (ratio >90%, <110%)
or hypometabolic (ratio <90%).251 it is not known if the hypometabolic response is an
energy efficient response carrying a better prognosis or if it carries a worse prognosis as a
'harbinger of adverse events to come'.251 it has been suggested that the difference in
mortality between different types of ARF is due to differences in metabolic status.277
The respiratory quotient (RQ) reflects net substrate oxidation at the time of measurement
and is derived from measurement of VO2 and VCO2. It is the ratio of CO2 produced to O2
consumed. The normal value is 0.7 - 1.0; values >1.0 are due to non steady state
hyperventilation (which should settle) or a continuous infusion of parenteral nutrition in
excess of energy requirements resulting in net lipogenesis. A RQ <0.7 occurs during
starvation and ketosis.
The APACHE II score is a valid marker of physiological stress. REE has been shown to
correlate with severity of illness, but its measurement is time consuming.764 jf ti,e
APACHE II score and REE both reflect physiological stress, it may be simpler to use the
APACHE II score as part of a predictive equation to estimate REE. I examined the
relationship between REE and the APACHE II score to determine whether or not the
APACHE II score could be used in this way.
7:2 Subjects and methods
7:2:1 Subjects
Twenty patients were enrolled into the study (Appendix 3). There were 7 males and 13
females, average age 60.7 years (range 24 - 80). All had acute renal failure with a serum
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creatinine >180umol/l. Five were ventilated. All ventilated patients had an inspired oxygen
concentration (Fi02) <0.6; patients requiring an FiC>2 >0.6 were not included due to
inaccurate measurement of VO2 at higher FiC>2 levels. All non ventilated patients had a
good oxygen saturation (>95%) breathing air.
7:2:2 Measurement of REE and RQ
All measurements were performed at the patients' bedside using an open system indirect
calorimeter, DELTATRACTM MBM-100. Measurements were performed at the time of
referral to the renal unit or ICU (measurement 1) and again after at least 48hours
(measurement 2).
The calorimeter was calibrated before each period of metabolic monitoring. Pressure
calibration was done using actual barometric pressure at the time of the test. Following this
gas calibration was performed using separate bottles of O2 and CO2, as opposed to a
mixture of both gases. All equipment coming into contact with patients' skin, expired air
and secretions was either disposed of or sterilised after use.
For patients not on a ventilator measurements of REE were made using a canopy. All
canopy measurements were performed on patients able to breath room air. A hose (A)
connected the canopy to the flow generator inlet (B) on the DELTRATRACTM (Figure
7:1). The outlet of the canopy (C) was placed close to the mouth of the patient. Sampling
of inspired air was done through the inspiratory sample line (D) placed at the air inlet (E) of
the canopy where pure ambient air was sampled. The plastic sheet (F) surrounding the
canopy was folded under the pillow so that the air inlet was the only entrance for air.
Patients were not allowed to fall asleep as this would result in a falsely low measurement.
Talking was not allowed as this would cause a rise in the CO2 concentration in the canopy
and prevent equilibration. Figure 7:2 is a photograph of the indirect calorimeter (canopy
mode) in use on a patient.
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For patients who were ventilator dependent a disposable 22mm tube (A) connected the
expiratory outlet of the ventilator (B) to the mixing chamber inlet (C) of the calorimeter
(Figure 7:3). A 22mm stainless steel adapter (D) attached to the inspiratory sample line (E)
was inserted in the inspiratory tubing of the ventilator at the outlet of the humidifier. The
sampling port for inspired gas was at least 50cm from the patient's Y piece to avoid
contamination with expired air.
For both ventilator and canopy measurements results were displayed at one minute intervals.
The length of the test varied and was determined by how long it took to achieve a steady
state and obtain five consecutive artefact free readings.
7:2:3 Measurement conditions 262
1. Patients must have rested in the supine position for at least thirty minutes prior to
measurement of REE.
2. To avoid the transient rise in REE in the post absorptive state, measurements were made
at least four hours after any oral intake or on patients receiving a constant rate infusion of
parenteral nutrition.
3. Measurements were made in a thermoneutral environment.
4. Patients were asked not to perform any voluntary movements during the measurements.
5. Any sources of supplemental oxygen were turned off during routine room air
measurements.
6. The sampling system was checked for leaks.
7. The data used to calculate REE and RQ were taken from a period of equilibration ie a
period of five or more consecutive one minute data points with a standard deviation for
both VO2 and VCO2 of <5% of the respective mean.
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7:2:4 Calculations
The REE is calculated using the Weir formula^ 18
REE = [3.941(VC>2) + 1.106(VCO2)J1.44 - 2.17(UN)
UN = 24 hour urine nitrogen excretion.
However, the difference between this and the abbreviated Weir formula^ 8
REE = [3.9(VC>2) + 1.1 (VCO2)]1.44
is less than 2% and therefore the abbreviated Weir formula was used to calculate REE.
The RQ was calculated as follows
RQ = VCO2/VO2
7:2:5 Statistical analysis
Measures of relationship were calculated by Pearson's correlation test. Mortality as a
variable was compared using chi-squared analysis. APACHE II scores were compared
using students' t-test. P values of <0.05 were taken to indicate statistical significance.
7:3 Results
The mean APACHE II score of the group was 16 ± 5.8. The causes of ARF are outlined in
Table 7:1. Patients had been in hospital for a mean of 3.75 days (range 2 hours - 24 days)
before referral. However, some patients had been convalescing after elective surgery before
deteriorating. All patients were referred within three days of becoming acutely unwell and
developing acute renal failure.
7:3:1 Measurement 1
Three patients (15%) had a RQ <0.7 implying starvation and/or ketosis. Five patients (25%)
had a measured REE that was > 10% below the predicted REE and were therefore
hypometabolic. 60% were initially hypermetabolic and 15% normometabolic.
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There was no correlation between the initial measurement of REE and APACHE II score
(Table 7:2). I adjusted the measured REE for size by dividing REE by BSA but still could
not show any correlation between the adjusted REE and the APACHE II score. Nor could I
show any correlation between measured REE and a number of other variables (Table 7:2).
Table 7:3 shows the relationship between independent variables and the percentage
difference in measured REE from predicted, ie 100% - (REE/HBREE)%. The measured
REE ranged from 35% below to 64% above the predicted value.
7:3:2 Measurement 2
Repeat testing after 2 days showed 54% to be hypometabolic, 23% normometabolic and
23% were hypermetabolic. Once again there was no correlation between REE
(measurement 2) and the initial APACHE II score. Nor was there any correlation between
the APACHE II score and the percentage difference in measured REE from predicted. This
time the measured REE ranged from 57% below to 21% above the predicted value The
percentage difference in measured REE from predicted was significantly lower after 2 days
in the renal unit or ICU (10.8% v -8.2%, p=0.03, admission v after at least 2 days
respectively), and as noted above 54% of patients were now hypometabolic.
7:3:3 Hypometabolic v hypermetabolic
Patients were divided into two groups based on their initial REE (hypometabolic and
hypermetabolic) and the drugs being prescribed at the time of testing were compared. The
hypometabolic group were not taking more sedating medication than the hypermetabolic
group, although those patients who were most hypermetabolic were receiving pressor
agents. The APACHE II scores in the hypermetabolic and hypometabolic groups were 16.6
± 6 and 14.4 ± 6.4 respectively (p=0.5).
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Mortality between the three groups (hypometabolic, normometabolic and hypermetabolic)
was compared and no difference was found (p=0.96).
7:4 Discussion
7:4:1 Results of study
I compared the APACHE II score at the time of referral to the renal unit or ICU with the
REE measured at the time of referral and again after a minimum of two days and could not
show any correlation between the two. In 1987 Swinamer et al measured REE in ten
mechanically ventilated ICU patients and showed that the degree to which REE exceeded
predicted EE correlated significantly with the admission APACHE II score (r=0.64,
p<0.02).268 The metabolic studies were performed 7±4 days after admission to ICU. I
could not confirm this finding in our group of patients either on admission or several days
after admission. When I excluded any patient who did not have metabolic measurements
and an APACHE II score calculated within 24 hours of admission I still could not show any
correlation between the two variables.
Swinamer et al published a second study examining the relationship between the APACHE
II score and REE in 112 mechanically ventilated, critically ill patients and could not show
any correlation between the APACHE II score and the REE measured within 48 hours.321
This time they did not compare the APACHE II score with the percentage difference
between measured EE and predicted EE.
After I had started this work a second group showed a statistically significant correlation
(r=0.2, p<0.001) between the APACHE II score and the measured EE in seventy critically
ill patients.322 They adjusted the measured EE to obtain the REE by eliminating the effects
of fever and diet induced thermogenesis and the REE was still significantly related to the
APACHE II score (r=0.18, p<0.001). Further adjustment of true REE to take account of
size by dividing true REE by BSA resulted in an even greater correlation with the APACHE
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II score (r2=0.23, p<0.001). I also adjusted the measured REE for size by dividing REE by
BSA but could not show any correlation between the adjusted REE and the APACHE II
score (p=0.6).
In this study the difference in measured REE from predicted on admission was significantly
different to the percentage difference after at least 2 days in the renal unit or ICU (10.8% v -
8.2% respectively, p=0.03) and more patients were hypometabolic (25% v 54%, initial
measurement v after at least 2 days respectively). After the initial measurement of REE
several of the patients were being sedated which very likely contributed to the
hypometabolic response. There was no difference in severity of illness at presentation
between the hypometabolic and hypermetabolic groups and, in this study, there was no
difference in mortality between the two groups.
As mentioned before most disease states increase REE and in general the more severe the
injury the greater the metabolic response.267 There appears to be a physiological plateau of
energy expenditure (EE) reached in response to injury that is approximately twice the REE.
Further insults do not cause a rise in REE because respiratory and circulatory responses are
already maximal.270,323 However, not all patients develop the hypermetabolic
response.264,319,324 Some are normometabolic and up to 15 - 20% are hypometabolic.
Some authors have attributed hypometabolism to the oxygen debt of anaerobic
metabolism.325 Others suggest that a decrease in VO2 and EE may be the earliest event
preceding cardiac instability.326
7:4:2 Potential sources of error
There are many potential sources of error when measuring REE by indirect calorimetry.
First, any change in the concentration of inspired oxygen will affect the REE.264
Particular attention therefore, must be paid to ensuring that there are no air leaks around the
canopy. Ventilators cannot be relied upon to deliver a stable Fi02, particularly at high O2
7-8
concentrations. Therefore, indirect calorimetry cannot be used on any ventilated patient
requiring an FiC>2 >60%.
Second, there was a huge variability in the percentage difference in measured REE from
predicted. This highlights the heterogeneous nature of a group of critically ill patients.
Swinamer also showed a marked variability in the percentage difference between measured
EE and predicted EE (measured 34 ± 19% above predicted, range -11% to 82%).321 jn
their study patients with low values tended to sleep most of the time, while those with
higher values were undergoing stressful procedures. Thus, the physical state of the patient
has a significant impact on the REE, emphasising that the measurements must be performed
on an awake patient in the resting state.
Third, Weissman et al monitored critically ill patients in ITU for a twenty-four hour period
and showed that EE ranged from -10% to 23% around a "steady state REE".324 REE
measured on different days showed a variability of 15%, and the more critically ill the
patient the greater the variability - REE 46% (range 37% - 56%) in the more severely ill
patients compared to 12% (range 4% - 18%) in the less ill patients in ICU. My two
measurements were carried out at the same time of day and under the same measurement
conditions in order to minimise variability.
7:5 Conclusion
More severely ill patients have been shown to have a higher APACHE II score and some
have a rise in REE. However, some patients may be normometabolic and 15 - 20% may
even be hypometabolic.270
I could not show any correlation between the APACHE II score calculated at the time of
referral and the REE measured at the time of referral and again after at least 2 days. This
may have been because, despite being severely ill, a large number of the patients (25%)
were hypometabolic. There was no significant difference in severity of illness between the
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hypometabolic and hypermetabolic groups nor was there any difference in mortality.
Whether or not a hypometabolic responds heralds a better prognosis is not clear, although
these results would suggest that this is not so. The second time REE was measured 54% of
patients were hypometabolic, mainly due to the effect of drugs. The APACHE II score was
not repeated at this time.
Indirect calorimetry is an accurate way of measuring energy expenditure in the critically ill
patient, and as such is a marker of physiological stress. The APACHE II scoring system
accurately determines severity of disease. The lack of correlation with the REE means that
the APACHE II score cannot be used as part of a formula to predict energy expenditure.
Serial measurements ofREE using indirect calorimetry are required.
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Figure 7:1 Canopy measurements ofREE
Figure 7:2 Patient demonstrating use of the indirect calorimeter (canopy mode)
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Figure 7:3 Ventilator dependent measurements ofREE
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Table 7:1 Cause of acute renal failure
Cause of acute renal failure Number
Infection / septic shock 9






Acute liver failure (alcohol) 1
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Table 7:2 Relationship between measured REE and independent variables
Variable r Value p Value
APACHE II score 0.09 0.7
Cardiac output 0.4 0.08
Temperature 0.4 0.07
Respiratory rate -0.103 0.7
MAP 0.03 0.9
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Table 7:3 Relationship between the 'percentage the measured REE differed
from predicted' and independent variables
Variable r Value p Value
APACHE II score 0.2 0.4
Cardiac output 0.14 0.6
Temperature 0.46 0.04
Respiratory rate -0.02 0.9
MAP -0.09 0.7
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8 Summary and Conclusions
'Acute renal failure is the result not of a specific sort of altered
kidney that can be given a name but of the formation of various
structural functional lesions in several million nephrons'.
Jean Oliver (1951)12
8:1 Pathogenesis of ischaemic acute renal failure
The pathogenesis of ischaemic acute renal failure is extremely complex. A number of
factors contribute to the development and progression of ARF namely decreased renal blood
flow,41 intratubular obstruction,41,42 backleak of filtrate,41 and vascular congestion.48,49
Less clear are the roles played by prostaglandins,28-80 free radicals 108 an(j calcium.95
To perform their function of absorption and secretion the renal tubules require an adequate
supply of oxygen. The anatomy of the nephron predisposes the medullary thick ascending
limb (mTAL) to hypoxia. The vessels and tubules of the medulla are arranged in a hairpin
loop manner which allows the exchange of solutes between the descending and ascending
limbs leading to efficient concentration of urine. Active transport of sodium in the mTAL
creates an osmotic gradient and is a high energy requiring process. Oxygen also diffuses
from the arterial to the venous branches of the vasa recta and therefore the oxygen supply to
the deeper parts of the medulla is reduced. In addition there is limited blood flow through
the medullary vessels to prevent washout of the solute gradients. Thus a limited blood
supply and a high oxygen requirement make the mTAL particularly susceptible to hypoxia
and '...medullary hypoxia is the unavoidable price we pay for the ability to concentrate our
urine'.53
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Several groups have shown that the medullary pC>2 is low and is in fact close to the pC>2
below which mitochondrial respiration is threatened. 52,327,328 One way of protecting the
kidney would be to reduce the energy required by the mTAL by modifying active
transport.286,287
8:2 Physiology of loop diuretic action
Loop diuretics are powerful diuretics which act mainly on the loop of Henle to prevent
sodium and water reabsorption. Some also prevent sodium reabsorption in the proximal
tubule. The distal tubules have a limited ability to reabsorb sodium and water and therefore
are not able to counteract the diuresis and natriuresis caused by the loop diuretic. Their
diuretic effect is due to their ability to bind to and inhibit the Na+K+2CL transporter in the
thick ascending limb (Figure 2:1) resulting in a fall in transcellular Na transport.' 79 Brezis
et al (1984) have shown that modifying transport activity with frusemide attenuates damage
to the mTAL.287 44 ± 2% of mTALs in kidneys perfused with glucose were severely
damaged compared to 7 i 2% in kidneys also perfused with frusemide (p<0.001).
Acetazolamide, which exerts its diuretic action on the proximal tubule, had no protective
effect on the mTAL.
More recently the same group have measured the medullary PO2 in rat kidneys perfused
with frusemide and shown that inhibition of active transport with frusemide increased
medullary PO2 from 16±4mmHg to 35±4mmHg (p<0.0005) without affecting cortical
PO2.286 Thjs effect was thought to be due to decreased tubule oxygen consumption as
medullary blood flow (measured by laser-Doppler probe) was significantly reduced by
frusemide (-28 ± 6% from baseline, p<0.0001). These effects were reproduced by
ethacrynic acid and bumetamide. Acetazolamide on the other hand, had no effect on
medullary PO2 but increased cortical PO2 by a selective reduction in proximal tubule
metabolism. Cortical blood flow was not affected by acetazolamide. Loop diuretics,
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therefore, increase medullary oxygen availability. Epstein et al showed an increase in the
oxidative state of cytochrome aa3 after the addition of loop diuretic to perfusate.329
The beneficial effect of loop diuretics on medullary PO2 led me to wonder if loop diuretics
might attenuate ARF by reducing tubular reabsorptive work and thus, in theory, make more
ATP available for regeneration.
8:3 Study 1 - effect of loop diuretics in ARF
Clinical studies of loop diuretics in ARF have been limited by bad study design and poor
control groups. The outcome of these studies is shown in Table 8:1. The results are
inconclusive, although all authors agree that a large enough dose of diuretic will increase
urine output to some extent in the majority of patients.
I carried out a double blind, randomly allocated, placebo controlled, prospective study to
examine the effect of loop diuretics in ARF. This study did not show any beneficial effect
on mortality, need for dialysis or duration of dialysis. Patients given a loop diuretic had a
significant diuresis and natriuresis compared to patients given placebo (Figures 5:1 and 5:2).
Those patients who became non-oliguric in the first 24 hours, either spontaneously (placebo
group) or pharmacologically induced (diuretic group), had a significantly lower mortality
compared to those who remained oliguric (43% v 69% respectively, p=0.001). However,
they were less ill (APACHE II score 17.2 ± 5.9 v 20.6 ± 5.5, p=0.008) and had less severe
renal failure at entry into the study (creatinine clearance 14 ± 11ml v 4 ± 4ml, p<0.0001).
I conclude that loop diuretics can indeed cause a diuresis in ARF which may help with fluid
balance. However, they do not affect the natural history of the disease and are not indicated
as definitive treatment.
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8:4 Study 2 - intraplatelet calcium in ARF
Elevated free cytosolic calcium has been proposed as the final common pathway of
ischaemic cell death.303 jt has been shown that intra-mitochondrial calcium rises following
reperfusion after experimental renal ischaemia, and that there is a significant correlation
between raised mitochondrial calcium concentration and decreased mitochondrial
respiration.94 Uncoupling ofmitochondrial respiration results in reduced ATP stores.94
Kramer et al showed that in an experimental model of ischaemic ARF, loop diuretics
prevented the rise in mitochondrial calcium normally seen in oliguric ARF.309 Loop
diuretics have been shown to decrease red cell [Ca]j in normal volunteers and patients with
essential hypertension.283,307 j hypothesised that a similar effect might occur in platelets
from patients with ARF who had been given loop diuretic, with the potential therefore for
less severe cell injury and a more favourable outcome.
Basal levels of [Ca]j were significantly higher in ARF patients than control subjects (109nm
v 92.4nm, p=0.04). In the presence of lmmol/1 calcium and AVP, which stimulates influx
of calcium from the suspension and release of intracellular stores of calcium into the
cytosol, the rise in the fluorescence signal tended to be higher in the control group, although
it did not reach statistical significance (584.8nm v 346nm, p=0.4). In the presence of
EGTA, which binds to any extracellular calcium, AVP caused a smaller rise in the
fluorescence signal in ARF patients compared to controls which again did not reach
statistical significance (116nm v 166nm, p=0.14). In this experiment the increased signal is
due solely to the release of intraplatelet stores of calcium and combined with the results
from the studies with AVP and 1 mmol/I calcium suggests that intraplatelet stores of calcium
are low in patients with ARF. This would not be surprising as ischaemia is known to alter
the composition of plasma membrane phospholipid.98,305 jn critically ill patients impaired
uptake and utilisation of oxygen would cause cellular hypoxia resulting in altered membrane
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composition which in turn would allow influx of extracellular calcium and efflux of
intracellular stores of calcium into the cell cytosol, resulting in high [Ca]j and low
intracellular stores. The study results tend to suggest that this is occurring. In addition the
fluorescence signal obtained from the ARF patients showed that the platelet membranes
were abnormally permeable to calcium (Figure 6:5).
The addition of loop diuretics had no effect on [Ca]j in patients with ARF. One possible
explanation for this is that alteration of cell membrane composition due to ischaemia may
alter drug binding sites so rendering them ineffective, unless given in a prophylactic manner
before the renal insult.
Since a rise in intracellular calcium is associated with illness,283,284 \ wondered if there
might be a correlation between the severity of illness reflected in the APACFIE II score and
the intraplatelet calcium level. However, I could not show any significant correlation
between the [Ca]j and the APACHE II score in ARF patients
8:5 Study 3 - resting energy expenditure and APACHE II score
Resting energy expenditure is affected by a number of factors as outlined in chapter 7. In
particular most disease states increase REE and in general the more severe the injury the
greater the metabolic response.266 However, some patients are normometabolic and 15 -
20% are hypometabolic.264 it has been suggested that the hypometabolic response may be
an energy efficient response carrying a better prognosis.264
The APACHE II score is a scoring system which can be used to stratify acutely ill patients
according to severity of illness, and the more ill the patient the higher the APACHE II
score.281 As the REE has also been shown to correlate with severity of illness I compared
the APACHE II score with the REE measured by indirect calorimetry in 20 patients with
ARF and a mean APACHE II score of 16 ± 5.8. I could not show any correlation between
the REE and APACHE II score measured on admission, even when the measured REE was
8-5
adjusted for size by dividing REE by BSA. This may have been because 25% of the
patients were hypometabolic at the time of the first measurement of REE. There was no
significant difference in severity of illness between the hypometabolic and hypermetabolic
group (APACHE II score 14.4 ± 6.4 and 16.6 + 6 respectively, p=0.5), and the
hypometabolic response did not seem to portend a better prognosis as mortality was not
improved (40% v 50%, p=0.8, hypometabolic v hypermetabolic).
The REE measurement was repeated after at least 2 days (mean 5 days, range 2 - 11 days)
and 54% of patients were noted to be hypometabolic. This was thought mainly to be due to
the administration of sedative drugs which are known to reduce REE.
Indirect calorimetry is an accurate way of measuring energy expenditure in critically ill
patients and is thus is a marker of physiological stress. The lack of any correlation with the
APACHE II score means that the APACHE II score should not be used as part of a formula
to predict energy expenditure. Serial measurements of REE using indirect calorimetry are
required.
8:6 Conclusion
The nature of the pathogenesis of ARF provides many points for targeting therapeutic
intervention; manipulation of renal haemodynamics, prevention of intratubular obstruction,
prevention of tubule epithelial cell injury and restoration of tubule epithelial integrity.330
Loop diuretics have the potential to preserve tissue ATP by suppressing resorptive work,
preventing and reversing intratubule obstruction, increasing renal blood flow and, according
to some, reducing intracellular calcium levels. Their role in the management of ARF has
been unclear mainly due to the poor design of previous studies. My work provides
conclusive evidence that loop diuretics have no beneficial effect on the natural history of
ARF. This is confirmed at a cellular level where I was unable to detect any change in
cytosolic calcium concentration. Loop diuretics are thus are unable to reverse one of the
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effects of hypoxia that ultimately leads to cell death. Despite this they may still have a role
to play in ARF as they cause a significant increase in urine flow rate in some patients, which
in turn may make management of fluid balance easier.
As a result of these findings the routine use of loop diuretics in ARF is no longer standard
practice in the Royal Infirmary, Glasgow and Stobhill Hospital, Glasgow.
A rise in intracellular calcium is associated with illness and therefore might be expected to
correlate with the severity of illness and outcome as measured by the APACHE II
score.283,284 i could not demonstrate any correlation between the APACHE II score and
[Ca]j in patients with ARF.
Similarly REE is affected by illness266 ancj it js possible that those patients with a higher
REE have a worse prognosis. Once again I could not demonstrate any correlation between
the APACHE II score and REE in patients with ARF.
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Appendix 1- Screening Data
Torasemide group




l 65 18.7 11
3 43 9.8 14
8 35 13.6 16
12 26 4.7 25
13 0 0.0 22
15 36 7.5 14
20 53 50.6 18
21 19 13.2 32
28 7 16.0 16
29 7 17.0 17
36 6 23.0 23
38 15 2.4 18
42 28 11.5 20
48 0 0.0 19
49 42.5 1.7 18
51 31 5.1 24
55 10.5 3.0 25
57 5 3.4 23
61 36 12.5 18
63 37.5 23.8 15
68 45 14.7 19
70 50 10.7 15
73 55 10.1 20
77 8 12.4 23
80 15 4.8 27
83 0 0.0 24
86 37.5 28.4 20
87 42.5 24.1 18
91 0 0.0 18
95 32.5 4.1 14
Appendix 1 (continued)
Frusemide group




2 12 3.4 16
6 21 2.3 14
7 75 10.6 12
ll 8 4.2 26
16 45 28.5 8
18 43.5 16.5 19
19 17 4.65 19
22 7 1.1 7
25 82 5.4 18
30 17.5 4.6 13
34 115 27.9 38
35 4 0.7 13
37 17 3.9 37
39 192 10.6 11
46 13.5 15.6 18
47 5 0.8 23
50 70 9.7 12
52 5 2.8 23
59 21.5 21.3 17
60 10 3.7 18
62 3 0.2 -
64 28 5.0 13
67 12.5 2.3 13
76 0 0.0 19
78 39 37.6 22
79 0 0.0 27
82 5 1.3 25
89 25 12.9 21
90 32.5 2.7 20
92 0 0.0 27
93 0 0.0 25
97 17.5 10.2 18
Appendix 1 (continued)
Placebo group




4 13.5 1.0 14
5 15 0.6 14
9 0 0.0 25
10 10 3.0 32
14 22.5 9.5 14
17 13 2.4 23
23 17.5 18.2 21
24 7.5 3.2 -
26 32.5 3.3 14
27 26.5 1.3 23
31 52.5 3.0 -
32 22.5 24.3 -
40 22 7.2 11
41 52.5 1.6 15
43 7.5 3.0 19
44 25 25.1 15
53 5 1.0 23
54 15.5 - -
56 19 - 9
58 0 0.0 17
66 21 11.3 11
69 30 7.6 20
72 0 0.0 15
75 70 29.0 18
81 24.5 13.1 24
84 10.5 10.4 10
88 19 14.2 19
94 7 3.4 27
96 6 3.0 24
98 14.5 4.9 21
Appendix 2 - Outcome at day 21
Torasemide group
Patient Outcome Time to Duration of Time to renal Urine output at
dialysis dialysis (days) recovery (days) 24 hours (ml/hr)
(days)
1 Alive 4 2 11 104
3 Alive - - 2 285
8 Alive - - 1 353
12 Dead - - - -
13 Dead - - - 0
15 Dead 16 4 - 287
20 Alive - - 1 300
21 Dead - - - -
28 Dead - - - 56
29 Dead - - - -
36 Alive 10 15 18 3
38 Dead 1 4 - 59
42 Dead 2 8 - 96
48 Dead 1 4 - 0
49 Dead 4 3 - 41
51 Dead - - - 45
55 Dead - - - -
57 Dead - - - -
61 Dead 3 2 7 212
63 Alive - - 2 395
68 Dead - - - 427
70 Alive 11 3 - 197
73 Dead - - - 267
77 Dead - - - 32
80 Dead 2 5 - 33
83 Dead - - - 0
86 Dead - - - 76
87 Dead - - - 48
91 Alive 1 10 17 5
95 Alive - - 3 47
Appendix 2 (continued)
Frusemide group
Patient Outcome Time to Duration of Time to renal Urine output at
dialysis dialysis (days) recovery (days) 24 hours (ml/hr)
(days)
2 Dead 3 DD - 67
6 Alive-DD 3 DD - 133
7 Alive - - 1 450
11 Dead - - - 777
16 Alive - - 1 -
18 Alive 14 DD - 231
19 Alive - - 4 75
22 Alive 16 DD - 7
25 Alive - - 2 260
30 Alive - - 1 207
34 Dead - - - 202
35 Alive - - 7 5
37 Dead - - - 8
39 Alive - - 2 170
46 Dead - - - 25
47 Dead 1 3 - 12
50 Alive - - - 131
52 Dead - - - 3
59 Dead - - 2 175
60 Dead - - - -
62 Dead - - - -
64 Alive - - - 130
67 Alive 6 11 18 23
76 Dead 18 DD - 0
78 Dead - - - 156
79 Dead - - - 12
82 Dead - - - 0
89 Alive 2 5 10 0
90 Dead - - 4 300
92 Dead 1 3 - 0
93 Dead 1 DD - 0
97 Dead - - 2 148
DD - dialysis dependent
Appendix 2 (continued)
Placebo group
Patient Outcome Time to Duration of Time to renal Urine output at
dialysis dialysis (days) recovery (days) 24 hours (ml/hr)
(days)
4 Dead - - 2 322
5 Alive - - 6 54.8
9 Dead - - - -
10 Dead - - - -
14 Alive - - 2 207
17 Dead - - - 1
23 Dead - - - 160
24 Dead - - - -
26 Alive 2 DD - 33
27 Alive - - 5 35
31 Alive-DD 1 DD - 9
32 Alive 2 2 4 52
40 Alive-DD 5 DD - 54
41 Alive - - 5 79
43 Dead 4 12 - 7
44 Alive - - 2 105
53 Dead-DD 2 DD - 50
54 Dead - - - -
56 Alive 3 3 7 43
58 Dead - - - 0
66 Alive 3 12 17 18
69 Alive 3 12 19 23
72 Alive 4 DD - 0
75 Alive - - 3 107
81 Dead - - - 25
84 Alive - - - 33
88 Alive 2 15 19 25
94 Dead - - - -
96 Dead - - - 0
98 Dead 2 2 - 19
DD - dialysis dependent
Appendix 3
Patients enrolled in study 3 (chapter 7)
Patient Cause of ARF APACHE II score Ventilated
1 Scleroderma crisis 11 No
2 Bronchopneumonia, respiratory failure 16 No
3 Aminoglycoside nephrotoxicity 18 No
4 Perforated oesophagus 14 No
5 Infection 14 No
6 Aminoglycoside nephrotoxicity 12 No
7 Septic shock 32 Yes
8 Acute liver failure (alcohol) 25 No
9 Bacterial pneumonia 14 No
10 Fungal infection of Hickmann line 8 No
11 Post aortic-bifemoral graft (elective) 23 Yes
12 Thrombotic thrombocytopenic purpura 19 No
13 Post aortic-bifemoral graft (emergency) 19 Yes
14 Septic shock 14 Yes
15 Gallstone pancreatitis 17 No
16 Shigella infection 13 No
27 Post aortic-bifemoral graft (elective) 13 Yes
18 Haemolytic uraemic syndrome 11 No
19 Goodpastures syndrome 11 No
20 Rhabdomyolysis 15 No
